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CHAPTER 1. 
THE LYSOSOMAL SYSTEM 

1.1. FUNCTION OF LYSOSOMES 
Lysosomes are part of the vacuolar system of the cell and these organelles 
are mainly responsible for the degradation of a variety of biological 
macromolecules derived from both extracellular and intracellular 
constituents. In a mammalian cell there can be several hundred 
lysosomes, most of which are located in the perinuclear area of the cell. 
The heterogeneous shape, size and inner stlUcture of lysosomes are 
reflected in the morphological nomenclature (residual bodies, dense 
bodies, multivesicular bodies). Certain stimuli, such as storage material, 
inflammation, ischemia, trauma or hormones can activate the lysosomal 
system. 
Lysosomes have a complement of over 40 enzymes, including proteases, 
nucleases, glycosidases, lipases, phosphatases and sulfatases each 
responsible for hydrolyzing a well-defined chemical linkage. The 
lysosomal membrane provides protection against degradation of the 
cytosol by the cell's own acid hydrolases. Lysosomal enzymes have in 
common an acidic pH optimum between 3.5 and 5.0. This pH 
environment is established by an ATP-dependent proton pump in the 
lysosomal membrane. 
Following the discovery of the lysosome by biochemical fractionation of 
cell extracts by de Duve and coworkers 40 years ago (de Duve et al., 
1955), the subcellular visualization of lysosomes using enzyme 
cytochemistry (acid phosphatase) suggested that lysosomes form as 
vesicles budding off the GERL-compartrnent (Golgi-Endoplasmic 
Reticulum-Lysosomes; Novikoff et al., 1964). Over the last decade this 
view has changed as a result of the identification of the mannose 6-
phosphate receptor (MPR), the definition of lysosomal membrane 
proteins, more specific markers of the Trans-Golgi Network (TGN) and 
the various compartments of the endocytic system in combination with 
the development of advanced irnrnunoelectron microscopic techniques 
(reviewed by Kornfeld, 1992). In the current view the lysosome is a 
dynamic cell organelle closely related to the biosynthetic and endocytic 
systems (reviewed by Sahagian and Novikoff, 1994). 
1.2. SUBSTRATE DELIVERY PATHWAYS TO L YSOSOMES 
The entry of substrates e.g. (glyco)proteins, (glyco)lipids, polysaccharides 
and nucleic acids into lysosomes is essential for their effective 
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degradation. The uptake and digestion of extracellular materials is called 
"heterophagy" (also referred to as endocytosis), whereas degradation of 
intracellular constituents is called "autophagy" (see figure 1). 
Heterophagy 
In the process of heterophagy there are several mechanisms, including 
phagocytosis, pinocytosis and receptor-mediated endocytosis. In all three 
processes the plasma membrane plays a crucial role in enclosing the 
extracellular material. 
Phagocytosis is restricted to specialized cells such as macrophages, 
eosinophils and neutrophils, which ingest micro-organisms, senescent 
cells and tumor cells. This process requires a specific interaction between 
material to be digested and the cell surface, a process mediated by cell 
surface receptors (Griffin et aI., 1975; Silverstein, 1989). After binding to 
the plasma membrane the engulfed particulate material forms a 
phagosome, which is transformed into a phagolysosome. Characteristic 
of phagocytosis is that the size of the phagosome is determined by the 
dimension of the engulfed material. The transformation of phagosomes 
into phagolysosomes is a dynamic process in which fusion events with 
early and late endosomes (see figure 1) are involved (Pitt et aI., 1992; 
Desjardins et aI., 1994). 
In contrast, vacuoles derived from pinocytosis (also referred to as fluid-
phase endocytosis) have a more homogeneous size. Pinocytosis is a non-
selective uptake of extracellular material by fluid-phase endocytosis 
(Watts and Marsh, 1992; Sandvig and VanDeurs, 1994), which in special 
cases can give rise to distinct endosome populations (Hewlett et aI., 1994). 
Both phagocytosis and pinocytosis uptake often leads to lysosomal 
degradation of the engulfed material. 
The process of receptor-mediated endocytosis is involved in many 
cellular functions, including nutrient uptake, clearance of plasmaproteins, 
uptake of viruses, binding and uptake of hormones and growth factors 
and subsequent mediating signal transduction (reviewed by Smythe and 
Warren, 1991; Trowbridge et aI., 1993; Bu and Schwartz, 1994). It provides 
a selective uptake mechanism for efficient (1000 fold increase compared 
to non-selective uptake) internalization of particular ligands. More than 
25 different receptors have been described that can take part in receptor-
mediated endocytosis (Browne and Greene, 1991). In general, receptor-
mediated endocytosis starts with the binding of the ligand to surface 
receptors and subsequent clustering in clathrin-coated pits. The latter is 
dependent on interactions between the receptors and a multisubunit 
complex called "HA-II adaptors" (Pearse and Robinson, 1990; Robinson, 
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Figure 1. Schematic diagram of a cell depicting the pathways of substrate delivery 
to Iysosomes from extracellular sources (heterophagy; A) and intracellular constituents 
(autophagy; B). A: 1 =phagocytosis, 2=receptor-mediated endocytosis, 3=pinocytosis. 
B: 1 =macroautophagy, 2=microautophagy, 3=crinophagy, 4=direct delivery via specific 
transporters. 
1994). This complex binds to the cytoplasmic tail of the receptor, in which 
the presence of a tyrosine residue in a generic sequence pattern of 4- and 
6- residue signals is essential. It is suggested that this tyrosine 
internalization signal surrounded by hydrogen-bonding residues gives 
rise to a type I B tight turn, which might be needed for a receptor to 
recognize HA-II adaptors (Collawn et aI., 1990; Ktistakis et aI., 1990; 
Eberle et aI., 1991). Membrane proteins that lack a tyrosine-containing 
signal (FcIIB2-receptor, CD4, GLUT4) can participate in receptor-mediated 
endocytosis by means of a di-leucine sequence motif in their cytoplasmic 
domain (Trowbridge et aI., 1993; Corvera et aI., 1994). 
Recently, it was shown in polarized MDCK cells that LDL and Fc 
receptors possess either tyrosine or di-leucine containing signals for 
basolateral sorting whereby the amino acids in the vicinity of these motifs 
determine whether they function for endocytosis, basolateral sorting or 
both (Matter et aI., 1994). 
The receptor-ligand complex enters the cell via invagination of the coated-
pit, forming a clathrin-coated vesicle. These vesicles lose their clathrin and 
form an endosome by fusion with each other. Since extracellular fluid is 
also trapped by this pathway in a non-selective manner in the endosomes, 
it implies that receptor-mediated endocytosis is also involved in fluid-
phase endocytosis. 
On the basis of the final destination of both receptor and ligand five 
intracellular routes can be distinguished (see figure 2): 
1. Receptor and ligand dissociate in the endosome, receptor is recycled to 
the surface or to the TGN and the ligand is degraded in lysosomes 
(LDL-receptor, MPR, asialoglycoprotein-receptor). 
2. Receptor and ligand both recycle to the plasma membrane (transferrin-
receptor). 
3. Both receptor and ligand are transported to lysosomes (EGF-receptor, 
PDGF-receptor, insulin-receptor). 
4. Ligand-receptor complex is delivered to the opposite side of polarized 
cells, where the ligand is released and the receptor is either degraded 
or recycled. This process is known as "transcytosis" (IgA-receptor, IgG-
receptor). 
5. Ligand and receptor dissociate in the endosome, receptor is recycled to 
the surface or TGN and ligand is released from endosomes (viruses, 
toxins). 
The endocytic pathway to be followed is cell type specific and determined 
by factors, such as receptor distribution, valency and type of ligand. 
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Figure 2. Schematic diagram showing the intracellular sorting pathways of receptor-mediated endocytosis, All five different pathways have in 
common the clustering in coated pits of receptor (R) and ligand (L), internalization of receptor-ligand complex and subsequent transport to 
endosomes, A; receptor recycles and ligand is degraded within Iysosomes, B; receptor and ligand recycle, C; receptor and ligand are degraded, 
D; transcytosis of receptor and ligand, E; receptor recycles and ligand is released in cytoplasm, Lysosomes are hatched, (8u and Schwartz, 1994) 
The mechanism by which endosomes are transformed into lysosomes is 
still controversial. In the "vesicle shuttle" model, vesicles budding from 
the early endosomes recycle to the cell surface or deliver their contents 
into late endosomes. Movement from the late endosome to lysosomes 
could occur in the same fashion. Thus, in this model early endosomes, 
late endosomes and lysosomes exist as stable, functional organelles, hence 
the name vesicle shuttle model (Griffiths and Gruenberg, 1991). 
Alternatively, in the "maturation" model early endosomes are transformed 
in late endosomes and then into lysosomes by a remodeling process. The 
endosome and lysosome identity is transient, but the vesicles they interact 
with and that modify them are stable (Stoorvogel et aI., 1991; Murphy, 
1991; Dunn and Maxfield, 1992). A third model was proposed by Hopkins 
(Hopkins et aI., 1990) who visualized a continuous endosomal reticulum 
by fluorescence microscopy in combination with video recording. Endo-
cytosed material moves via multivesicular bodies along this reticulum. 
Autophagy 
Cells also need lysosomes to degrade their own components. This process, 
termed autophagy, is as complex as heterophagy. On the basis of the size 
of the segregated material a distinction can be made between "macro-
autophagy" and "rnicroautophagy". 
In the early stage of macroautophagy, large intracellular components 
(mitochondria, membrane fragments) are sequestered in autophagosomes 
by enclosing the cellular material. The limiting membranes of these 
autophagosomes are derived from the endoplasmic reticulum (Dunn, 
1990a), subsequently a fusion with endosomes occurs that are 
transformed to lysosomes (Tooze et al., 1990; Dunn, 1990b; PUlIDonen et 
aI., 1993). Smaller cytosolic components, like glycogen particles and 
soluble proteins appear to be taken up by rnicroautophagy, a process 
whereby the endosomal/lysosomal membrane invaginates. Multiple 
events of microautophagy result in endosomes referred to as 
"multivesicular bodies" (Marzella and Glaumann, 1987). Studies from 
Kopitz and coworkers (Kopitz et aI., 1990) yielded similar sequestration 
and degradation rates for normal cytosolic proteins with varying half-
lives, suggesting that microautophagy occurs by a nonselective bulk 
process. Furthermore, it has been proposed that degradation of 
internalized EGF-receptor and perhaps other selected integral proteins of 
the endocytic boundary is established by multiple events of micro-
autophagy (Hopkins, 1992), mediated by distinct sequences in the 
carboxyl terminus regulatory region (Opresko et aI., 1995). Advantages of 
autophagy are cell rejuvenation and adaptability, but this process is 
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primarily a response to food deprivation. 
A special kind of autophagy is named "crinophagy". This process occurs 
in gland cells as a result of fusion between secretory granules and 
lysosomes. The destruction of secretory material may serve as a 
mechanism for modulating the level of secretory material available for 
export (Farquhar, 1969). Secretory proteins can also be degraded at the 
level of the endoplasmic reticulum (ER) by direct conversion of ER 
cisternae into lysosomes (Noda and Farquhar, 1992). 
An alternative route for entering lysosomes was recently reported for 
proteins that contain a KFERQ-like peptide sequence. It was suggested 
that a specific transporter in the lysosomal membrane recognizes these 
signals and transports these cytosolic proteins in a highly selective 
manner directly across the lysosomal membrane (Chiang et a!., 1989; Dice, 
1990). 
A second alternative substrate entry pathway was described by Rome and 
coworkers (Rome et a!., 1983; Bame and Rome, 1985). The lysosomal 
membrane enzyme, acetyl CoA:a-glucosaminide N-acetyltransferase 
(Klein et a!., 1978) is responsible for transferring acetyl groups from 
cytosolic acetyl CoA across the lysosomal membrane whereafter they are 
bound to the terminal a-linked glucosamine residues of heparan sulfate 
that are localized in the lysosomal lumen. 
Acid hydrolases in the lysosomes convert their substrates by irreversible 
reactions. This degradation occurs often by the sequential stepwise 
removal of components such as sugars from glycolipids, glycoproteins 
and proteoglycans. The basic building blocks formed by the digestive 
process, such as amino acids, sugars and nucleotides, diffuse or are 
transported by special carrier systems across the lysosomal membrane 
into the cytoplasm, where they can be reutilized (reviewed by Pisoni and 
Thoene, 1991). The products of digestion that cannot be cleared ultimately 
accumulate in the lysosomes forming structures called "dense bodies". 
1.3. BIOSYNTHESIS AND TARGETING OF LYSOSOMAL PROTEINS 
Lysosomal enzymes are glycoproteins which are synthesized on 
membrane-bound ribosomes and translocated into the lumen of the 
endoplasmic reticulum. For the majority of the lysosomal enzymes this 
process is mediated by an amino-terminal signal peptide (reviewed by 
Rapoport, 1991; Ng and Walter, 1994). Proteins lacking signal peptides 
can be translocated across the endoplasmic reticulum membrane by 
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means of a nascent-polypeptide-associated complex (NAC; Wiedmann et 
aI., 1994). After translocation the signal peptide is proteolytically removed 
cotranslationally by a signal peptidase (Von Heyne, 1983). In the rough 
endoplasmic reticulum (RER) N-linked glycosylation starts with 
cotranslational transfer en bloc of a large high mannose oligosaccharide 
(Glc3Man"GlcNAcz) from a lipid carrier (dolichol). During transport 
through the RER, the precursor is folded and the oligosaccharide 
undergoes a first trimming modification i.e. removal of glucose. In the 
Golgi complex further posttranslational modifications occur (Goldberg, 
1987). 
mannose 6-phosphate dependent pathway 
Most (soluble) lysosomal enzymes obtain subsequently phosphorylated 
mannose residue(s}. The latter is accomplished in a two step reaction: N-
acetylglucosamine-1-phosphate binding to mannose residues and removal 
of N-acetylglucosamine. The enzymes responsible for these reactions are 
N-acetyl-glucosamine-phosphotransferase and N-acetylglucosamine-1-
phosphodiester N-acetylglucosaroinidase, respectively (Goldberg, 1987). 
The arising mannose 6-phosphate residue acts as a recognition marker for 
the mannose 6-phosphate receptor (MPR) (Kornfeld and Mellman, 1989; 
Kornfeld, 1992). 
Two MPR's have been identified (reviewed by Kornfeld, 1992); a large 
(275 kDa) receptor, independent of divalent cations (CI-MPR; Sahagian, 
1981) which is identical to the insulin-like growth factor II receptor and 
a small (46 kDa) receptor, that binds ligands· in a divalent cation 
dependent manner (CD-MPR; Hoflack and Kornfeld, 1985). The receptors 
share structural homology and their coding sequences are derived from 
a common ancestor gene. Both MPR's are localized predominantly in the 
TGN, however, their steady state distribution may differ between 
different cell types (Geuze et aI., 1984 and 1985; Willemsen et aI., 1988; 
Griffiths et aI., 1988; Bleekemolen et aI., 1988). MPR's are also present at 
the plasma membrane and in endosomes, although differences for both 
receptors in endosomal distribution are reported (Klumperman et aI., 
1993). Targeted disruption of the CD-MPR gene in mice exhibited partial 
missorting of lysosomal enzymes and subsequent increased secretion of 
multiple lysosomal enzymes in serum (Koster et aI., 1993; Ludwig et aI., 
1993). This hypersecretion was partly compensated by significant uptake 
mediated by carbohydrate-specific receptors (Koster et aI., 1994). 
Fibroblasts prepared from embryos lacking the CI-MPR also exhibit a 
partial missorting of several lysosomal enzymes. However, the secreted 
hydrolases belong to a different subset of lysosomal enzymes compared 
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to the secreted hydrolases from CD-MPR-negative fibroblasts (Ludwig et 
aI., 1994). These results clearly demonstrate that both receptors are 
required for an efficient intracellular targeting of lysosomal enzymes to 
lysosomes, and that they interact with different but overlapping classes 
of hydrolases. Embryonic fibroblasts lacking both MPR's revealed 
completely impaired targeting of multiple lysosomal enzymes (Ludwig 
et aI., 1994). 
It has now been generally accepted that both MPR's bind mannose 6-
phosphate containing lysosomal proteins in the TGN. Receptor-ligand 
complexes are clustered in clathrin-coated pits, that pinch off from the 
TGN. Clustering of both MPR's and thus efficient sorting in TGN is 
dependent of di-leucine motifs in the cytoplasmic tail, that are believed 
to mediate the interaction with HA-1 adaptor complexes of clathrin-
coated pits of the TGN (Johnson and Kornfeld, 1992a and 1992b). 
Interestingly, these di-leucine signals were unable to promote receptor-
mediated endocytosis at the plasma membrane (Lobel et aI., 1989). In 
addition, the tyrosine containing internalization signal of the CI-MPR can 
mediate targeting to coated pits of the TGN as well (Johnson and 
Kornfeld, 1992a). This phenomenon of two sorting signals for lysosomal 
targeting has also been described for CD3 chains (Letourneur and 
Klausner, 1992). Recently a third function of cytoplasmic tyrosine-
containing motifs was assigned in mediating TGN localization of TGN38, 
a resident TGN protein (Humphrey et aI., 1993). 
The coated vesicles lose their coat and fuse with the acidified endosomal 
compartment, where the receptor and ligand dissociate at the acidic pH. 
MPR's recycle to the TGN or the plasma membrane, while the lysosomal 
enzymes remain in the lumen of the endosome. The enzymes are then 
together with endocytosed proteins transported to lysosomes (Kornfeld 
and Mellman, 1989; Ludwig et aI., 1991). Thus, lysosomes are virtually 
devoid of MPR's. 
Newly synthesized lysosomal enzymes with mannose 6-phosphate 
residues that were not sorted out in the TGN by the MPR's and instead 
secreted can bind to the CI-MPR present at the plasmamembrane 
(Kornfeld, 1986). These lysosomal enzymes are captured via receptor-
mediated endocytosis and transported by the endosomal system to 
lysosomes. The CD-MPR is unable to bind ligands at neutral pH at the 
plasma membrane and is therefore not involved in this process (Stein et 
aI., 1987; Tong and Kornfeld, 1989). 
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mannose 6-phosphate independent pathwa1/s 
As described above MPR's playa major role in targeting of newly 
synthesized lysosomal enzymes, however, additional or alternative 
transport routes have been considered. 
The following observations suggested the existence of alternative MPR 
independent pathways. In cultured fibroblasts from Mucolipidosis II (1-
cell disease) and Mucolipidosis III patients (reviewed by Kornfeld and 
Sly, 1995) a near normal activity (Leroy et aI., 1972; Hickman and 
Neufeld, 1972; Vladutiu and Rattazzi, 1975) and localization (Van Dongen 
et aI., 1984; Van Dongen et aI., 1985; Parenti et aI., 1987) was observed for 
some lysosomal enzymes (e.g. acid phosphatase, glucocerebrosidase). In 
these disorders the formation of the mannose 6-phosphate recognition 
marker is defective, because the enzyme N-acetylglucosamine-l-
phosphotransferase is deficient. A characteristic feature of both disorders 
is the secretion of many lysosomal enzymes, since these proteins are not 
effectively sorted in the TGN by the MPR's (Kornfeld, 1986). For acid 
phosphatase, an integral membrane protein, it was demonstrated in 
transfected BHK cells that molecules are probably transported to the 
plasma membrane via the constitutive secretory pathway. On arrival they 
cycle on average 15 times between the plasma membrane and the 
endosomal compartment before entering the lysosomes (Braun, 1989). 
Intralysosomal proteolytic cleavage revealed a soluble form of the enzyme 
(Gottschalk et aI., 1989). The presence of a tyrosine residue in the 
cytoplasmic domain of acid phosphatase is necessary for a correct 
lysosomal targeting, presumably because the enzyme needs this aromatic 
residue to enter clathrin coated pits at the plasma membrane (Peters et aI., 
1990; Sosa et aI., 1993). 
The mechanisms by which glucocerebrosidase, a membrane-associated 
enzyme, is transported to lysosomes are not well characterized. 
Quantitative immunocytochemical studies on intestinal epithelial cells 
suggest a direct pathway from TGN to lysosomes (Willemsen et aI., 1991), 
but details of this targeting are still unknown. 
Importantly, liver tissue and leucocytes from I-cell disease patients have 
near normal activities of lysosomal enzymes, suggesting that there is 
another pathway for directing lysosomal enzymes to lysosomes in these 
cells and other tissues (Owada et aI., 1982; Waheed et aI., 1982). Perhaps 
other receptors, like mannose receptors or asialoglycoprotein receptors 
are used to capture secreted lysosomal enzymes and target them via 
receptor-mediated endocytosis to lysosomes. 
A second indication for the existence of a mannose 6-phosphate 
independent pathway is the fact that glucocerebrosidase and integral 
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Figure 3. Simplified scheme showing the proposed intracellular transport pathways 
for soluble, membrane bound and membrane-associated lysosomal enzymes. (Adapted 
from Van der Ploeg, 1989). 
lysosomal membrane proteins (lgp-A and 19p-B group, acid phosphatase) 
do not contain a mannose 6-phosphate recognition marker on their N-
linked oligosaccharides in normal cells (Krentler et ai., 1986; Barriocanal 
et ai., 1986; Waheed et ai., 1988; Howe et ai., 1988; Aerts et ai., 1988; 
Granger et ai., 1990). 
The pathway by which lysosomal membrane proteins are delivered to 
lysosomes is still controversial (reviewed by Fukuda, 1991; Peters and 
Von Figura, 1994; Sandoval and Bakke, 1994a). The presence of lysosomal 
membrane proteins from the 19p-A as well as the 19p-B group at the 
plasma membrane (Lippincott-Schwartz and Fambrough, 1987; Carlsson 
and Fukuda, 1992; Mathews et ai., 1992) and the fact that the plasma 
membrane expression was increased by mutations affecting the cyto-
plasmic tyrosine domain (Williams and Fukuda, 1991; Harter and 
Mellman, 1992) would favor a transport pathway for at least part of the 
19p's from the TGN via the plasma membrane and endosomal system to 
lysosomes, as described for lysosomal acid phosphatase. However, it can 
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not be excluded that this tyrosine internalization residue is also necessary 
for sorting in clathrin-coated buds from the TGN. Mutation of this 
tyrosine might result in missorting and thus transport via the constitutive 
pathway to the plasma membrane. Lysosomal targeting of LimpII, an 
integral lysosomal membrane glycoprotein lacking a tyrosine residue, is 
mediated by a specific extended configuration of a leucine-isoleucine 
motif in the cytoplasmic tail (Ogata and Fukuda, 1994; Sandoval et aI., 
1994b). This motif can function also for rapid internalization. 
Alternatively, kinetic studies on lysosomal membrane proteins have 
suggested a direct pathway from the TGN to lysosomes via endosomes 
(D'Souza and August, 1986; Green et aI., 1987). Altering the tyrosine 
internalization signal in 19p-A blocks the direct intracellular route to 
lysosomes too, which implicates that sorting in the TGN for 19p-A 
requires also tyrosine containing signals (Harter and Mellman, 1992). 
1.4. Lysosomes and storage diseases 
The concept of a lysosomal storage disease was for the first time 
described in 1963 by Hers (Hers, 1963) for a disorder called glycogenosis 
type II, caused by the deficiency of acid a-glucosidase. The deficiency of 
this enzyme leads to accumulation of glycogen in lysosomes from skeletal 
muscle and heart. At the present time more than 30 different lysosomal 
storage disorders have been reported, nearly all of which are inherited in 
an autosomal recessive manner. Thusfar, two X-linked lysosomal storage 
disorders are known i.e. mucopolysaccharidosis II (Hunter's disease) and 
Fabry's disease. The incidence at birth of lysosomal disorders varies from 
1 in 100,000 to 1 in 250,000. However, in certain ethnic groups like 
Ashkenazi Jews the incidence of some lysosomal disorders like Gaucher 
disease (1 in 625) and Tay-Sachs disease (1 in 3,000) is much higher. The 
total group of lysosomal storage disorders has an incidence of 
approximately 1:5,000 to 1:10,000 (Galjaard and Reuser, 1984; Reuser et aI., 
1994). 
Most lysosomal enzyme deficiencies result in the dysfunction of many 
organs, though in a different degree. Microscopic studies often reveal 
abnormalities in shape, size and content of the lysosomal system. These 
abnormalities are sometimes specific for a certain group or a single 
lysosomal storage disease (Scriver et aI., 1995). 
The clinical presentation among lysosomal disorders is extremely 
heterogeneous. Also within each of the diseases clinical heterogeneity is 
often observed. Some patients have an early onset form with very severe 
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symptoms leading to serious handicaps and early death. Others have a 
milder variant of the disease with onset later in childhood or even (late) 
adulthood. A patient with a lysosomal enzyme deficiency may have an 
asymptomatic course. The etiology of clinical diversity has been an 
interesting area of research in lysosomal storage diseases. 
In the past a correlation between clinical heterogeneity and biochemical 
parameters was sought. This has led to the "critical threshold" theory 
(Conzelmann and Sandhoff, 1983). In this model it is assumed that 
lysosomal storage develops when the residual activity of the mutant 
enzyme is below a critical threshold. Above the threshold the residual 
activity is by definition just sufficient to cope with the influx of substrate, 
and hence no storage, cell damage or clinical abnormalities occur. 
Differences in the residual enzyme activity below a critical threshold 
could significantly affect the severity of pathological and clinical features, 
but differences in levels of enzyme activity above the threshold would 
have no effect. 
More recently, studies on clinical heterogeneity have focused on the allelic 
diversity by analysis of the genotype of patients with different variants 
of a specific lysosomal storage disease. The majority of the gene defects 
in lysosomal storage diseases are point mutations. Most patients appear 
to be compound heterozygotes i.e. they have different mutations in their 
alleles. However, in some patients deletions of nucleotide(s) or exons, 
insertions of nucleotides and splicing defects have been observed. 
Furthermore, other factors such as genetic background or non-genetic 
factors may influence the clinical heterogeneity observed in patients 
suffering from a lysosomal storage disease. 
As described in section I.3., synthesis, maturation and correct targeting of 
lysosomal enzymes involve transcription, translation and often post-
translational modifications. In principle, dysfunction of a lysosomal 
enzyme can be caused by defects in any of these steps. These defects can 
be caused by mutations in the gene of a lysosomal enzyme, that leads to: 
1. No or erroneous transcription, resulting in absence or reduced levels 
of mRNA or unstable mRNA and as a consequence no protein 
synthesis. 
2. Other mutations might result in enhanced degradation of newly 
synthesized protein in the RER or lysosomes, because the protein is not 
folded correctly. 
3. Mutations that result in impaired post-translational modification can 
lead to incorrect compartmentalization or secretion, enhanced 
degradation, or impaired function in the lysosomes. 
4. Dysfunction of proteins involved in post-translational modification of 
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lysosomal enzymes can also give rise to a lysosomal storage disorder 
(Kornfeld and Sly, 1995). 
5. The primary defects of most lysosomal storage diseases involve the 
deficiency of a specific lysosomal enzyme. However, defects in proteins 
that influence either the stability of lysosomal enzyme(s), as in the case 
of the protective protein (0' Azzo et aI., 1982), or the activity as a result 
of abnormalities of activatorproteins (Furst and SandhoH, 1992) may 
also result in a lysosomal storage disease. 
6. The impaired export of low molecular weight degradation products out 
of the lysosomes by dysfunction of the carrier proteins which are 
located in the lysosomal membrane have recently been identified as a 
new group of lysosomal storage diseases (Mancini, 1991; Pisoni and 
Thoene, 1991). 
In the next chapter the most common lysosomal storage disorder i.e. 
Gaucher disease will be discussed in more detail. 
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CHAPTER II 
GLUCOCEREBROSIDASE AND GAUCHER DISEASE 

ILl. HISTORICAL PERSPECTIVE 
In 1882, the French physician Philippe Charles Ernest Gaucher described 
the autopsy findings in a 32 year old patient with an enlarged spleen, that 
he concluded resulted from a primary splenic neoplasm (Gaucher, 1882). 
The familial occurrence of the disorder, which subsequently became 
known as Gaucher disease, was reported in 1901 (Brill, 1901). Three years 
later, the occurrence of Gaucher cells in the bone marrow was described 
(Brill, 1904), and 30 years later the "hyaline substance" in these cells was 
identified as glucosylceramide or glucocerebroside (Aghion, 1934). In 1920 
the first case of Gaucher disease in an infant was reported (Kraus, 1920) 
and the severe neurologic involvement of the infantile form of the disease 
was emphasized in 1927 (Oberling and Woringer, 1927). 
The primary metabolic defect of the disease was demonstrated in 1965 
(Brady et a!., 1965; Patrick, 1965) when the deficiency of the lysosomal 
enzyme glucocerebrosidase was identified in tissues from patients with 
Gaucher disease. The description of the primary defect and the 
availability of natural and artificial substrates provided the basis for 
enzymatic diagnosis of affected individuals and prenatal diagnosis of 
affected fetuses (Kampine et a!., 1966; Beutler and Kuhl, 1970; Schneider 
et a!., 1972). Increased levels of the neurotoxin glucosylsphingosine, a 
deacylated analogue of glucocerebroside, in neuronopathic variants was 
demonstrated in 1982 by Svennerholm and coworkers (Nilsson and 
Svennerholm, 1982). 
Purification of glucocerebrosidase and the preparation of monospecific 
antibodies against the enzyme enabled investigators to discriminate the 
different molecular forms of the enzyme in healthy individuals and 
Gaucher patients (Ginns et a!., 1982 and 1983; Barneveld et a!., 1983) and 
to confirm its lysosomal membrane association in vivo (Willemsen et a!., 
1987). Cloning of the human gene encoding for glucocerebrosidase (Ginns 
et a!., 1984; Sorge et a!., 1985; Tsuji et a!., 1986) made it possible to 
identify a large number of mutations that cause Gaucher disease (Beutler, 
1993; Horowitz and Zimran, 1994). In addition, enzyme replacement 
protocols were developed using modified human placental glucocere-
brosidase (Barton et a!., 1991). 
The identification of the human gene permitted the development of gene 
therapy strategies. The mouse glucocerebrosidase cDNA was described 
in 1989 (O'Neill et a!., 1989). A mouse model for type 2 Gaucher disease 
has been generated by targeted disruption of the mouse glucocere-
brosidase gene, also referred to as a "knock-out" or "null-allele" mouse 
(Tybulewicz et a!., 1992). 
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IL2. CHARACTERISTICS OF GLUCOCEREBROSIDASE AND ITS 
INTERACTION WITH SAPOSINS 
The human glucocerebrosidase gene is located on chromosome 1q21 and 
is comprised of 11 exons and 10 introns contained within 7604 base pairs. 
The promotor region is located approximately 150 base pairs upstream to 
exon 1. The gene has five potential N-glycosylation sites, but only four of 
the asparagine residues are glycosylated (Takasaki et al., 1984). Studies of 
normal and mutated cDNA's in Sf9 and COS-1 cells showed that Asn-462 
was not glycosylated. In addition, these studies demonstrated that 
glycosylation of the first asparagine residue (Asn-19) is critical for the 
synthesis of a catalytically active enzyme (Berg-Fussman et al., 1993). Two 
functional ATG initiator codons have been identified (Sorge et al., 1987). 
The downstream ATG was translated more efficiently resulting in a 19-
amino acid signal polypeptide which contains a hydrophobic core (Reiner 
et al., 1987). The cDNA contains 1548 base pairs encoding functional 
glucocerebrosidase. No transmembrane domains are identified in the 
protein, but short hydrophobic stretches in the carboxy-terminal part of 
the enzyme probably play a role in the membrane association of 
glucocerebrosidase (Barranger and Ginns, 1989). The enzyme's specific 
activity varies enormously between different cell types. This may reflect 
variation in protein synthesis or degradation (Doll and Smith, 1993). A 
glucocerebrosidase pseudogene has been identified 16 kB downstream 
from the functional gene. This pseudogene has many missense mutations 
and deletions that prevent synthesis of active enzyme (Horowitz et al., 
1989). 
The enzyme is synthesized in the endoplasmic reticulum and the signal 
peptide is cotranslationally cleaved by signal peptidase. The asparagine 
residues are core glycosylated (Erickson et al., 1985). The apparent 
molecular weight of the 63 kDa nascent polypeptide is increased to 66 
kDa by converting the oligosaccharides predominantly to complex-type 
structures with terminal sialic acid residues. On the average 20% of 
human placental enzyme contain high-mannose chains (Takasaki et al., 
1984). Glucocerebrosidase processing with complex carbohydrate occurs 
as the enzyme moves through Golgi cisternae. Differential 
permeabilization of pulse-labelled cells with saponin initially revealed a 
more soluble glucocerebrosidase that became membrane associated as the 
higher molecular form appeared (Rijnboutt et al., 1991). This would 
suggest that the membrane association occurs between exit from the 
endoplasmic reticulum and arrival in the TGN. 
In the lysosomes further modifications of the enzyme oligosaccharide 
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chains by exoglycosidases occur, resulting in a decrease of the molecular 
weight to 59 kDa. Thus, after cotranslational cleavage of the signal 
peptide no additional proteolytic processing occurs in the post-
translational modification of glucocerebrosidase. The transport mechanism 
from the TGN to the lysosomes is unknown. It has been demonstrated for 
other hydrolases that targeting to lysosomes can occur via a MPR-
independent pathway (see chapter I). The membrane association of 
glucocerebrosidase might be essential for its correct lysosomal localization 
as was speculated in studies of the subcellular localization of soluble and 
membrane-bound lysosomal enzymes in I-cell fibroblasts (VanDongen et 
al., 1985). Comparative quantitative studies of soluble, membrane 
associated and membrane-bound lysosomal enzymes in human intestinal 
epithelial cells revealed a labelling pattern that was most compatible with 
a transport pathway leading directly from the TGN to the lysosomes 
(Willemsen et aI., 1991). 
There have been reports of glucocerebrosidase isoenzymes (Glew et aI., 
1988), including a non-lysosomal membrane-bound B-glucosidase (CBE-
insensitive) that hydrolyzes glucocerebroside at less acidic conditions than 
lysosomal glucocerebrosidase (CBE-sensitive). This CBE-insensitive 
enzyme is not deficient in patients with Gaucher disease (VanWeely et aI., 
1993). Discrimination between lysosomal and non-lysosomal glucocere-
brosidase activity was achieved by pretreatment of cells with CBE. The 
biological function of the non-lysosomal enzyme is thusfar unknown. 
The acid exohydrolases that degrade sphingolipids in the lysosomes work 
in concert with small nonenzymic glycoproteins, called "sphingolipid 
activator proteins" (SAP's) for effective interaction with the substrates 
(Sandhoff et aI., 1995). The SAP's are encoded by two genes on 
chromosome 5 and 10, carrying the genetic information for the 
ganglioside GM2 activator and prosaposin, respectively. Proteolytic and 
glycosidic processing of the 70 kDa molecular form of prosaposin 
generates saposin A, B, C, and D. All four of these peptides contain 
conserved cysteine and proline residues (reviewed by O'Brien et aI., 1991; 
Furst and Sandhoff, 1992; Kishimoto et aI., 1992). Saposin C enhances the 
in vivo hydrolysis of glucocerebroside by glucocerebrosidase and is one 
of the four heat-stable glycoproteins involved in spingolipid hydrolysis. 
The other three, saposin A, Band D, stimulate the hydrolysis of gluco-
and galactocerebroside, sulfatides and ceramides (Klein et aI., 1994), 
respectively. Effective reconstitution of glucocerebrosidase activity in vitro 
requires negatively charged phospholipids (e.g. bile salts or anionic lipids) 
or saposin C (spingolipid activator protein-2)(Ho and O'Brien, 1971). 
Saposin C stimulates glucocerebrosidase by forming a complex with the 
27 
enzyme. The formation of such aggregates might lead to conformational 
changes, thereby resulting in a more active enzyme. Other acidic lipids 
(e.g. phosphatidylserine) are also capable of forming aggregates and 
activate glucocerebrosidase, though to a lesser extent than saposin C. 
Using phosphatidylserine-containing vesicles it has been found that 
saposin C is also capable of destabilizing and fusing phospholipid-
containing bilayers, thereby creating a situation by which glucocere-
brosidase can insert into the membranes (Vaccaro, 1994). 
Prosaposin is transported to the lysosomes in a MPR-dependent manner, 
which explains the deficiency of saposin C in I-cell fibroblasts 
(Fujibayashi and Wenger, 1985). Immunoelectronmicroscopic studies on 
the subcellular localization of saposin C demonstrated association of the 
activator protein with the lysosomal membrane (Paton et aI., 1990). The 
importance of saposin C in the degradation of glucocerebroside is 
illustrated by the severe clinical manifestations resulting from the 
deficiency of the activator protein (Christomanou et aI., 1989; Harzer et 
aI., 1989). 
11.3. CLINICAL PHENOTYPE 
Gaucher disease is the most prevalent inherited lysosomal storage disease 
and belongs to the sphingolipidoses. This group of disorders results from 
deficiencies of lysosomal enzymes that degrade glyco-sphingolipids and 
sphingomyelin. On the basis of the presence and degree of neurologic 
involvement (Table 1), Gaucher disease has been classified into three main 
clinical types: type 1 (chronic, non-neuronopathic), type 2 (acute, 
neuronopathic) and type 3 (subacute, neuronopathic) (Beutler and 
Grabowski, 1995; Grabowski, 1993). All these clinical types are caused by 
a deficiency of glucocerebrosidase. In other instances a deficiency of 
saposin C has been reported to result in a glucocerebroside accumulation. 
Identification of the primary metabolic defect permitted studies in which 
a correlation was sought behl'een protein defect and clinical phenotype. 
Cloning of the human gene led to the identification of at least 50 different 
mutations within the gene for glucocerebrosidase. Mutation analysis 
enabled investigators to study the relation between genotype and clinical 
phenotype. 
The incidence of type 1 Gaucher disease is approximately 1:50,000 
newborns in the general population, with variable onset of symptoms that 
may appear in childhood or remain unnoticed until far into adulthood. 
In general, the earlier the onset of the clinical symptoms the more severe 
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Table 1. Clinical manifestations of Gaucher disease. 
Type I Type 2 Type 3 
(chronic, non neuronopathic) (acute, neuronopathic) (subacute neuronopathic) 
Presentation very heterogeneous more stereotypic heterogeneous 
Age presents at any age presents at 0-6 months usually in childhood 
Progression variable death by age 2-3 years neurologic abnormalities 
by adolescence 
Cornmon signs hepatosplenomegaly hepatosplenomegaly hepatosplenomegaly 
bone involvement seizures bone involvement 
anemia / thrombocytopenia trismus supranuclear ophthalmoplegia 
strabismus rare: slowly progressive 
hyperreflexia dementia, seizures and 
spasticity 
Genetics · autosomal recessive autosomal recessive autosomal recessive 
· increased incidence no ethnic predilection panethnic with a 
· among Ashkenazirn rare Norrbottnian subgroup 
rare 
the course of the disease. The phenotypic variability of type 1 Gaucher 
disease ranges from asymptomatic or mildly affected patients to children 
with massive hepatosplenomegaly, skeletal abnormalities and sometimes 
fatal complications. The development of a "knock-out" mouse model of 
Gaucher disease led to the emphasis of a severely affected type 2 Gaucher 
phenotype in human neonates, with clinical manifestations that may 
include ichthyotic skin and/or hydrops fetalis as associated symptoms 
(Sidransky et aI., 1992). 
Clinical phenotype in relation to protein defect 
Glucocerebroside (or glucosylceramide), the major natural substrate for 
glucocerebrosidase, is synthesized from ceramide and UDP-glucose by 
glucosylceramide synthase (Glew et aI., 1988) and is primarily present in 
cell membranes. The sphingolipid also arises as an intermediate in the 
degradation pathway of glycosphingolipids, such as globosides and 
gangliosides. 
Glucocerebrosidase catalyzes the hydrolyses of the fS-glucosidic bond in 
glucosylceramide (figure 4, arrow) to yield glucose and ceramide, the 
latter being degraded by lysosomal acid ceramidase to sphingosine and 
fatty acid (Beutler and Grabowski, 1995; Grabowski, 1993a). The fatty acid 
chain length varies, the most abundant component being stearic acid (C
'S) 
in brain, and C,o to C'4 fatty acids in spleen, liver and blood cells. 
CH,oH 1 H 0/, 
HO~O,+.o / H HO~ 'CH, .,-,,:: 
OH H OH 
Figure 4. Structure of glucocerebroside. 
Although every cell in Gaucher patients is deficient in glucocerebrosidase 
the accumulation of glucocerebroside is most pronounced in macrophages 
of the mononuclear phagocyte system (reticulo-endothelial system). An 
important reason for this selective storage is the degradation of 
membranes of senescent red and white blood cells by tissue macrophages. 
However, it can not be excluded that uptake of lipoproteins, the carrier 
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Figure 5. High magnification electronrnicrograph illustrating typical Gaucher cell 
inclusion bodies which are filled with the characteristic tubule-like structures. 
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of plasma glucocerebroside, by macrophages contributes to the high level 
of storage material in these cells. The glucocerebroside that accumulates 
in macrophages gives the cytoplasm of these cells a characteristic striated 
appearance characteristic of "Gaucher cells". These cells, which are the 
hallmark of the disease, are 20-100 ).llIl in diameter and contain one or 
more nuclei often in an eccentric location. At the subcellular level it was 
demonstrated that the highly hydrophobic glucocerebroside molecules 
stored in the lysosomes give rise to bilayers that stack up as membranous 
sheets (see figure 5). It has been suggested that storage material can leak 
out from lysed Gaucher cells into the extracellular space (Pennelli et aI., 
1969; Hibbs et aI., 1970) and in this way be the source of 2-20-fold 
elevated plasma levels of glucocerebroside in Gaucher patients. It has 
been demonstrated that glucocerebroside can act as a growth factor 
(Radin, 1994). This stimulated cell division might explain the enlargment 
of spleen and liver in Gaucher patients. Increased secretion of lysosomal 
hydrolases and cytokines by stimulated macrophages as a response to 
extensive storage may contribute to the pathogenesis of the disease 
(Moffitt et aI., 1978; Gery et aI., 1981). Furthermore, it has been observed 
that hypersplenism can result from the striking increase in glycolipid 
turnover from blood cell membranes. It is likely that the rate of influx of 
substrate, the half-life of the enzyme, the lysosomal pH and the 
expression of saposin C in lysosomes (VanWeely et aI., 1993) all influence 
the quantity of stored material and in this way contribute to the 
heterogeneity of clinical manifestations. Also the inability of Gaucher cells 
to perform the normal functions of macrophages may contribute to the 
severity of the disease. 
Studies on the processing of glucocerebrosidase in cultured fibroblasts 
from Gaucher patients indicate that in type 1 Gaucher disease normal 
processing occurs, producing a lysosomal 59 kDa mature form with 
reduced activity to artificial substrate. In type 2 and 3 Gaucher fibroblasts 
only precursor (63 kDa and 66 kDa) and no mature (59 kDa) form of the 
enzyme could be detected. Lysosomes contained very little cross-reactive 
material, while RER and TGN were normally labelled (Ginns et aI., 1982 
and 1983; Willemsen et aI., 1987). These results suggest that in type 2 and 
3 Gaucher fibroblasts the enzyme either fails to reach the lysosome or is 
rapidly degraded within the lysosomes, and support the hypothesis of a 
deficient processing of glucocerebrosidase in type 2 and type 3 Gaucher 
disease. It is also suggested that the presence of sufficient residual activity 
in the lysosomes might preclude or postpone development of neurologic 
disease (Tsuji et aI., 1987; Willemsen et aI., 1987). In this respect it is of 
interest that a correlation between the residual glucocerebrosidase activity 
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in cultured fibroblasts and the clinical type of Gaucher disease was 
demonstrated, using short-acyl-chain sphingolipid analogues as substrate 
(Meivar-Levy et aI., 1994). 
Many patients develop skeletal manifestations with episodic bone crises 
during childhood and adolescence. A characteristic feature of skeletal 
changes is the "Erlenmeyer flask" appearance resulting from expansion of 
the bony cortex. The pathophysiology of bone lesions is largely unknown, 
but it is suggested that infiltration of Gaucher cells into the bone marrow 
may cause mechanical obstruction, replacement of normal marrow cells 
and toxic foci (Beutler and Grabowski, 1995). Alternatively, an imbalance 
in calcium homeostasis by reduced absorption of vitamin D and calcium 
has been suggested to playa role in the pathogenesis of bone disease 
(Mankin et aI., 1990). 
Reports on the central nervous system involvement in Gaucher disease 
are limited. In type 2 Gaucher patients microscopic abnormalities, 
including gliosis, neuronal loss and free Gaucher cells within brain 
parenchyma and perivascular spaces has been demonstrated (Norman et 
aI., 1956; Banker et aI., 1962; Adachi et aI., 1967; Espinas and Faris, 1969; 
Hernandez et a!., 1973; Kaga et aI., 1982; Lacey and Terplan, 1984; Kaye 
et aI., 1986). It is notable that the fatty acid of stored glucocerebroside in 
type 2 brain is predominantly stearic acid (CIS)' which is the major fatty 
acid in gangliosides and probably derives from ganglioside turnover. In 
type 3 Gaucher patients less severe central nervous system manifestations 
than seen in type 2 are generally observed (Conradi et aI., 1984; Kaye et 
aI., 1986). In cases with numerous Gaucher cells in the brain of type 3 
patients the proportion of C18 fatty acids is less than normal while C24 
fatty acids are increased. This might be explained by circulating 
glucocerebroside from extracerebral sources being taken up by 
perivascular Gaucher cells (Nilsson and Svennerholm, 1982). This would 
be in agreement with the observation that increased concentrations of 
glucocerebroside in plasma caused by splenectomy in type 3 patients 
result in enhanced accumulation of storage material and a larger number 
of Gaucher cells in brain (Conradi et aI., 1984) and impaired neurological 
function (Blom and Erikson, 1983). Neurons with characteristic storage 
material were encountered only sporadically (Banker et aI., 1962; Adachi 
et a!., 1967; Conradi et a!., 1984). 
In the brain the presence of cytotoxic substances may playa major role 
in the pathogenesis of type 2 and 3 Gaucher disease. In particular, the 
role of the neurotoxin glucosylsphingosine (glucosyl-psychosine), mainly 
derived from deacylation of glucocerebroside (Yamaguchi et a!., 1994) has 
been studied extensively. Nilsson and Svennerholm (1982) found 
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significant elevated levels of this neurotoxin in brain from type 2 and 3 
patients. Furthermore, lysosphingolipids, including glucosylsphingosine, 
inhibit protein kinase C activity and phorboldiester binding at very low 
concentrations, and might interfere with signal transduction and cellular 
differentiation processes (Hannun and Bell, 1987). This may disrupt 
neuronal function and cause neuronal cell death. It is conceivable that the 
failure to visualize significant amount of storage material in lysosomes of 
neurons is the result of low concentrations of the neurotoxin causing 
neuronal dysfunction or neuronal cell death before discrete pathological 
changes are seen. Also the extrusion of storage material from Gaucher 
cells within the brain parenchyma might contribute to local neuronal loss. 
The absence of neurological manifestations in patients with type 1 
Gaucher disease may be, because they have sufficient residual enzyme 
activity within the lysosomes of neurons to cope with the ganglioside 
turnover in the brain during development. 
Clinical phenotype in relation to genot1(pe 
All three phenotypes of Gaucher disease are caused by a deficiency of 
glucocerebrosidase. In addition, glucocerebroside storage has been 
reported as the result of mutations in saposin C and prosaposin (Harzer 
et a!., 1989; Christomanou et aI., 1989; Schnabel et aI., 1991). The broad 
clinical heterogeneity among Gaucher patients is attributed to more than 
50 different mutations within the gene for glucocerebrosidase, including 
missense, splice site, frame shift, and deletion mutations (reviewed by 
Beutler, 1993; Horowitz and Zimran, 1994). Thusfar, mutations have been 
found throughout the glucocerebrosidase gene. In the next section the 
four most common mutations will be discussed. 
Mutation N370S 
This G to A mutation at nucleotide 1226 of the cDNA of glucocere-
brosidase, results in the substitution of the amino acid serine for 
asparagine. Accounting for 70-75% of the mutated alleles among Jewish 
Gaucher patients and 23% in non-Jewish patients, it is the most prevalent 
mutation among Gaucher patients. The presence of the N370S mutation 
in one or both alleles seems to preclude the development of neurologic 
involvement and is therefore most predictive of type 1 Gaucher disease. 
Approximately 90% of the patients who are homozygous for this 
mutation have a late onset of symptoms and a mild clinical course 
(Zimran et a!., 1989 and 1992). It has been estimated that up to 66% of 
individuals homozygote for the N370S mutation are asymptomatic 
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(Zimran et ai., 1991; Beutler et ai., 1993). A moderate to severe clinical 
course was found in only 5% of the patients homozygous for N370S. In 
a recent study using lymphoblasts and fibroblasts from type 1 patients the 
relationship between intralysosomal pH and catalytic efficiency of the 
mutant N370S enzyme was investigated. Near normal kinetic properties 
of the enzyme were found if the assay was performed at the appropriate 
pH and in the presence of saposin C and phosphatidylserine, indicating 
a role of the pH in determining the state of activation of mutant 
glucocerebrosidase (VanWeely et ai., 1993). Overexpression of cDNA 
carrying the N370S mutation in Sf9 insect cells revealed a stable 
glucocerebrosidase protein with decreased catalytic rate constants and 
reduced binding to active site-directed inhibitors (Grace et ai., 1994). 
Mutation 84GG 
This insertion of an extra G at nucleotide 84 of the cDNA is the second 
most cornmon mutation among Ashkenazi Jewish patients (13%), whereas 
in the non-Jewish populations it account for less than 1% of the 
mutations. This produces a frameshift causing a premature stopcodon, 
and results in the production of unstable rnRNA and complete lack of 
enzyme protein. In the heteroallelic state this mutation is usually 
associated with type 1 Gaucher disease with severe clinical manifestations 
(Horowitz and Zimran, 1994). Patients homozygous for this "null" 
mutation have not been found. Homozygosity for 84GG may therefore be 
lethal in utero or shortly after birth, like the phenotype of the type 2 
Gaucher mouse created by targeted disruption of the murine glucocere-
brosidase gene (see appendix paper III). 
Mutation L444P 
This T to C substitution at nucleotide 1448 of the cDNA, results in a 
proline instead of leucine. It accounts for 50% of the mutated alleles in 
patients with neuronopathic Gaucher disease, but this mutation is also 
found in 30% of alleles in type 1 non-Jewish Gaucher patients, mostly in 
a heteroallelic state. All patients homozygous for the L444P mutation 
developed type 2 or type 3 Gaucher disease (Dahl et ai., 1988), whereas 
type 2 patients can also be heterozygous for the mutation. Homozygosity 
of L444P in the Japanese population is associated with non-neuronopathic 
Gaucher disease (Masuno et ai., 1990). 
Overexpression of the mutant cDNA in Sf9 insect cells resulted in the 
synthesis of unstable enzyme with very low catalytic activity and lack of 
stimulation by saposin C (Grace et ai., 1994). 
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Mutation IVS2+ 1 
This splice site mutation due to a G to A transition of the first nucleotide 
of the second intron destroys the 5' donor splice site. The low levels of 
aberrant mRNNs do not result in synthesis of active enzyme. It accounts 
for 1-3% of the mutated alleles among Jewish and non-Jewish Gaucher 
patients. The mutation is found in patients with both non-neuronopathic 
and neuronopathic Gaucher disease. Most patients with type 1 Gaucher 
disease carrying the genotype N370S/IVS2+ 1 developed moderate to 
severe Gaucher disease. 
It has been hoped that mutation analysis might permit both the reliable 
detection of carriers and the prediction of the clinical phenotype and 
course from the genotype. The first application is important for genetic 
counseling in families a t risk, particular in the Ashkenazi Jewish 
population. The second application is arduous due to the phenotypic 
variability that exists among patients with the same genotype and vice 
versa. This variability should be appreciated in counseling Gaucher 
patients (Sidransky et aI., 1994). 
11.4. THERAPY 
For the vast majority of heritable diseases, including the lysosomal 
storage disorders, there is no cure or adequate therapeutic treatment. The 
ultimate goal in treating a patient with a lysosomal storage disorder 
would be to provide sufficient enzymic activity in the lysosomes of 
affected cells. During a century of research on Gaucher disease several 
attempts have been made to successfully treat patients. Often the 
treatment has been directed toward symptomatic relief rather than 
correcting the enzyme deficiency, and has included total or partial 
removal of the spleen, transfusions and orthopedic procedures. However, 
over the last decade a number of procedures have been attempted to 
address the accumulation of lipid per se. In this section some of these 
procedures such as organ transplantation, cell transplantation, enzyme 
replacement therapy and somatic gene therapy will be discussed. 
Organ Transplantation 
A number of attempts to treat Gaucher patients by organ transplantation 
have been undertaken. Kidney, spleen and liver transplantation were not 
successful in improving clinical symptoms of the disease (Groth et aI., 
1971; Desnick et aI., 1973; Carlson et aI., 1990; Starzl et aI., 1993; Smanik 
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et aI., 1993}. In the case of other lysosomal storage diseases like Fabry 
disease it was also demonstrated that the transplanted organ did not 
create a source of sufficient amounts of exogenous enzyme that could be 
targeted to storage cells in the body or act as a substrate sink (Van 
denBergh et al., 1976). Organ transplantation may still be worthwhile in 
some cases. 
Cell Transplantation 
Transplantation of non-immunogenic amniotic membranes producing 
large quantities of lysosomal hydrolases, has been attempted as a therapy 
for several lysosomal storage disorders including mucopolysaccharidosis, 
GM, Morquio B, I-cell disease, metachromatic leukodystrophy, Farber 
disease, GM1 gangliosidosis, Tay-Sachs disease, Niemann-Pick type B 
disease and type 3 Gaucher disease (Tylki-Szymanska et aI., 1987; Yeager 
et a!., 1985; Scaggiante et a!., 1987; Sakuragawa et a!., 1992). The clinical 
effects resulting from amniotic tissue transplantation have been variable. 
Clinical improvements were reported in patients with Niemann-Pick type 
B disease (Scaggiante et a!., 1987) and type 3 Gaucher disease 
(Sakuragawa et al., 1992), whereas no significant improvements were 
observed in patients with other lysosomal storage disorders. Although 
there may be some clinical benefit for patients with certain lysosomal 
storage disorders the clinical use of amniotic tissue transplantats is still 
controversial and more research seems to be required to explore the 
efficacy of the procedure. 
Bone marrow transplantation (BMT) has also been used as a source of 
normal enzyme. BMT was initially used for the treatment of hematologic 
malignancies and aplastic anemias. Over the last decade, however, there 
have been reports of approximately 150 patients with a lysosomal storage 
disease who underwent BMT (Krivit et a!., 1992). In principle, BMT from 
a normal donor should provide a continuous source of a missing enzyme 
and should correct a metabolic defect by replacement of enzyme deficient 
cells with normal cells of hematopoietic origin. Uptake of secreted 
enzymes via receptor molecules at the plasma membrane or via enzyme 
transfer by cell to cell contact could occur (Bou-Gharios et aI., 1993). 
Since type 1 Gaucher disease primarily results from the accumulation of 
glucocerebroside in bone marrow-derived macrophages this type of 
Gaucher disease had been a good candidate for BMT, until enzyme 
replacement therapy became successful (Barton et a!., 1991). Until now 
seven type 1 patients were reported with bone marrow transplants from 
histocompatible siblings. Two patients died and five less severely affected 
patients are doing well (Rappeport and Ginns, 1984; Hobbs et a!., 1987). 
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Long-term follow up studies of BMT in six patients with type 3 Gaucher 
disease revealed a stable neurologic status (IQ between 112-120) (Erikson 
et a!., 1990; Ringden et a!., 1995). Even patients who became chimeras (20-
80%) showed an excellent clinical outcome (Erikson et a!., 1994; Chan et 
a!., 1994). Autopsy of a type 3 patient, who died of sepsis two years after 
BMT, demonstrated few Gaucher cells in liver and lung and absence of 
these storage cells in brain. Neuropathic manifestations had not 
progressed and a complete reconstitution of enzymatic activity in visceral 
organs was observed. However, glucocerebrosidase activity in brain did 
not increase (Tsai et a!., 1992). 
There is no evidence that membrane-associated glucocerebrosidase can 
cross the blood-brain barrier and subsequently be taken up by neurons. 
Therefore the underlying mechanisms that cause arrest of nervous system 
deterioration are not understood. It cannot be ruled out that the presence 
of large numbers of Gaucher cells in the perivascular space may cause 
leakiness in the blood-brain barrier. Entrance into the brain parenchyma 
of cells from hematopoietic origin that secrete lysosomal hydrolases might 
also contribute to the stabilization of the neurologic status. Electron-
microscopic studies of mucopolysaccharidosis type VII mice, twitcher 
mice, fucosidase deficient dogs and a-mannosidosis cats showed 
significant reduction after BMT in storage material in cells of non-
hemopoietic origin in brain such as neurons (Hoogerbrugge et a!., 1988; 
Birkenmeier et a!., 1992; Taylor et a!., 1992; Sands et a!., 1993; Walkley et 
a!., 1994; Poorthuis et a!., 1994). Secreted normal enzyme may be taken up 
by cells of non-hemopoietic origin, like neurons and glia, as demonstrated 
by enzyme cytochemistry (Hoogerbrugge et a!., 1988; Walkley et a!., 
1994), despite the low endocytotic activity- of neuronal cells in vitro 
(Rattazzi et a!., 1987). In addition, autologous transplanted retroviral 
marked mouse hematopoietic stem cells were identified in regions 
throughout the brain in which donor derived cells were shown to 
populate brain parenchyma as perivascular macrophages and microglia 
(Krall et a!., 1994). 
Reduction of storage material in blood might also lead to decreased levels 
of storage material in tissues as a result of a gradient of lipid between 
plasma and tissues (Barranger, 1984). Recent studies using lethally 
irradiated normal mice that were engrafted with fetal liver cells derived 
from the glucocerebrosidase-null mouse displayed no storage material in 
macrophages of the mononuclear phagocyte system one year after trans-
plantation. This suggests that storage of glucocerebroside in lysosomes of 
glucocerebrosidase deficient macrophages can be prevented either by 
uptake of enzyme from the blood circulation or by maintenance of normal 
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levels of glucocerebroside in plasma (McKinney et aI., 1995). 
There are no data available on BMT in type 2 Gaucher patients. However, 
BMT in patients with other infantile forms of lysosomal storage disorders 
with central nervous system involvement, did not show clinical 
improvement or arrest of neurologic manifestations (Krivit et aI., 1992). 
It is conceivable that irreversible neuronal damage develops during the 
first months of life. 
Interestingly, very recently it was shown that engraftment of neural 
progenitor cells, after injection into the lateral ventricles, corrects 
lysosomal storage throughout the brain in the mucopolysaccharidosis 
type VII mouse (Snyder et aI., 1995). 
Enzl{me Replacement Therapy 
The suggestion by de Duve in 1964 that enzyme replacement might be 
useful in the treatment of lysosomal storage disorders has become reality 
for individuals with type 1 Gaucher disease (De Duve,1964; Brady and 
Barton, 1994a, 1994b and 1994c). The first attempts at enzyme therapy for 
Gaucher disease began with the development of purification techniques 
for glucocerebrosidase from human placenta (Pentchev et aI., 1973). The 
initial clinical trials using human placental glucocerebrosidase were 
encouraging, but the subsequent experience was disappointing (Brady et 
aI., 1974, 1977, 1980; Beutler et aI., 1982). Uptake studies in rat liver 
showed that the purified human placental enzyme was predominantly 
targeted to parenchymal cells instead of the non-parenchymal cells 
(Furbish et aI., 1978; Morrone et aI.,1981). Further animal studies 
demonstrated that modification of the sugar chains into terminal mannose 
residues with exoglycosidases led to a significant increase of uptake by 
non-parenchymal liver cells, including Kupffer cells, via a mannose-
specific receptor (Furbish et aI., 1981). These observations resulted in the 
development of alglucerase (Ceredase™) and the effect of this modified 
enzyme on clinical manifestations was examined in twelve type 1 patients 
(Barton et aI., 1991). In addition to reduction in organomegaly and 
improvement of anemia, skeletal improvement has been suggested, albeit 
the latter lags behind the other parameters (Mankin, 1993). Analysis of 
more than 250 sera of patients treated with alglucerase displayed that 
approximately 13% of the patients developed antibodies against the 
enzyme, although, the clinical effectiveness of alglucerase was retained 
(Richards et at., 1993). 
The clinical trials with recombinantly produced glucocerebrosidase from 
CHO cells (Cerezyme™) have only recently started and the initial results 
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are promising, suggesting that it is as effective as alglucerase (Grabowski 
et aI., 1995). 
Alglucerase therapy has also been tried for neuronopathic Gaucher 
disease. In one case of type 2 Gaucher disease treated at 5 months of age 
with alglucerase infusions, no improvement of severe neurological 
manifestations were observed. Enzyme infusion therapy was stopped 
after seven months and the patient died four weeks later (Erikson et aI., 
1993). The severe neuronal damage developed in the first five months of 
life could not be reversed by alglucerase treatment, suggesting that 
enzyme therapy in type 2 patients if tried should be given well before 
neurological symptoms develop. The initial reports of alglucerase 
administration to type 3 Gaucher patients are encouraging (Zimran et aI., 
1993; Bembi et aI., 1994) and clinical trials with recombinantly produced 
glucocerebrosidase in these patients have recently started. 
More than 900 individuals worldwide are now successfully receiving 
alglucerase treatment. However, limited information is available about 
tissue, cellular and subcellular distribution of the enzyme. The half-life of 
alglucerase in Gaucher cells after infusion in humans is not well 
characterized (Whittington and Goa, 1992). This lack of pharmacokinetic 
and pharmacodynamic data is reflected in a controversy about the 
optimum dosage regimen and the efficacy of the treatment (Figueroa et 
aI., 1992; Pastores et aI., 1993; Hollak et aI., 1993; Zimran et aI., 1994). In 
a recent in vitro study it was reported that uptake of alglucerase at high 
enzyme concentrations by cultured macrophages is not efficient, and that 
endothelial cells are more effective in uptake of alglucerase (Sato and 
Beutler, 1993). The uptake of mannose terminated ligands by hepatic 
endothelial cells has already been reported using electronmicroscopic 
autoradiographic techniques (Hubbard et aI., 1979). 
It has also been suggested that the beneficial response to alglucerase 
therapy may be due at least in part, to the clearance of the storage 
material from the blood circulation (Sidransky et aI., 1993). Electron-
microscopic studies in mice and rats following intravenously 
administered alglucerase demonstrated that alglucerase is targeted to the 
endosomal/lysosomal system of both Kupffer cells and endothelial cells. 
The contribution of endothelial cell uptake of alglucerase to the beneficial 
response to therapy observed in Gaucher patients is still unknown, but 
the issue appears to be more complex than previously recognized 
(Willemsen et aI., 1995; Murray and Jin, 1995). Major disadvantages of 
alglucerase therapy include high cost ($200,000 per patient per year), 
contamination with placenta proteins and a requirement for life-long 
intravenous injections. 
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These uncertainties in our understanding of pathophysiologic mechanisms 
in Gaucher disease have stimulated the development of other approaches 
for enzyme replacement therapy in Gaucher disease e.g. poly-ethylene 
glycol (PEG) modified glucocerebrosidase. PEG modification of 
glucocerebrosidase prolongs the survival of the enzyme in blood and 
should permit use of lower doses and alternative routes of administration 
(Allen et aI., 1994). This strategy has been successful in the treatment of 
severe combined immunodeficiency (SCID) with PEG-modified adenosine 
dearninase (Hershfield et aI., 1987). A clinical trial of PEG-
glucocerebrosidase for the treatment of type 1 and 3 Gaucher disease is 
now in progress (Ginns, personal communication). 
The experience with enzyme replacement therapy in Gaucher disease may 
serve as a prototype for the treatment of other metabolic disorders, such 
as Pompe disease, Fabry's disease and Niemann-Pick disease type B. 
Delivery of the missing enzyme to the target (storage) cell may require 
other delivery strategies than those used in Gaucher disease. So far, 
various carrier proteins such as insulin (Poznansky et aI., 1989), low 
density lipoprotein (Williams and Murray, 1980), galaptin (Allen et aI., 
1990), fragment C of tetanus toxin (Dobrenis et aI., 1992) and a2-
macroglobulin (Tsuji et aI., 1994) have been proposed for the targeting of 
lysosomal enzymes. Much more research will be needed to develop 
effective treatment for inherited metabolic disorders with central nervous 
system involvement, particularly passage of the administered protein 
through the blood-brain barrier is required (Brownlees and Williams, 
1993). Interestingly, a recent study has demonstrated incorporation of 
mannose labelled liposomes into the mouse brain after intraperitoneal 
injection (Umezawa and Eto, 1988). In vitro targeting of IS-N-
acetylhexosaminidase A (Hex A) to neuronal lysosomes has been 
achieved in neuronal cell cultures by coupling Hex A to fragment C of 
tetanus toxin (Dobrenis et aI., 1992). However, in vivo studies are 
required to extend these findings. Enzyme replacement therapy with 
recombinant IS-glucuronidase in murine mucopolysaccharidosis type VII 
at 5 weeks of age resulted in partial correction of the lysosomal storage 
within specific neuronal cell populations (Sands et aI., 1994). 
Somatic Gene Theraptl 
The introduction of normal disease-related genes including those coding 
for a-D-galactose-1-phosphate uridyl transferase, IS-globin and 
hypoxanthine guanine phosphoribosyltransferase into the genome of 
target cells were the first experimental attempts at somatic gene therapy 
for heritable disorders (Merril and Geier, 1971; Mulligan and Berg, 1981; 
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Green et aI., 1982). The transfer of genes for somatic gene therapy has 
been attempted by two main approaches (Morsy et aI., 1993; Moseley and 
Caskey, 1993; Kay and Woo, 1994). One approach involves in vivo 
transfer of the gene directly into the affected cell or tissue. This method 
requires specific targeting in sufficient quantities to the appropriate cell 
type. Alternatively, the ex vivo delivery of the gene to target host cells 
followed by autologous cell transplantation is also being developed. For 
both approaches viral vectors and nonviral methods are used to achieve 
efficient gene transfer. 
Viral vectors 
The therapeutic gene is inserted in replication-defective viral vectors and 
propagated in helper cell lines that complement the deleted essential 
genes of the vector. Retroviruses, adenoviruses, adeno-associated viruses 
and herpes simplex viruses have been explored for somatic gene therapy 
(Ali et aI., 1994). Retroviruses have been used extensively because of their 
high efficiency of low copy number integration and permanent expression 
of the therapeutic gene. A major disadvantage of this virus system is the 
poor infectivity of nonreplicating cells (e.g. neurons) and the restriction 
to relatively short genes (Vile and Russell, 1995). Adenoviral vectors do 
not integrate into the genome and are gradually lost with cell division. As 
a consequence the therapeutic gene is expressed only in a transient 
manner. Adenoviral vectors are able to infect dividing and nondividing 
cells (Kremer and Perricaudet, 1995). Adeno-associated vectors (AAV) 
appear to integrate efficiently into a specific site on chromosome 19 in 
human cells. Recently, long-term expression of human tyrosine 
hydroxylase in mammalian brain was obtained using the AA V approach 
(Kaplitt et aI., 1994). Herpes simplex viruses are neuronotropic DNA 
viruses that do not integrate into the host genome, but exist as an 
episome that can be reactivated in infected neurons. Herpes simplex virus 
vectors are usually cytopathic and more studies are needed before they 
can be used for clinical trials (Efstathiou and Minson, 1995). 
Nonviral methods 
Alternatively, gene delivery can be accomplished using nonviral methods 
(Schofield and Caskey, 1995). Receptor-mediated endocytosis has been 
proposed as a mechanism to transfer genes into specific cell types 
(Wagner et aI., 1994; Frese et aI., 1994). Proteins that are ligands for 
specific receptors at the plasma membrane of the target cell are 
conjugated with DNA and these complexes can be subsequently 
internalized. To overcome lysosomal degradation and the low and 
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transient gene expression, the ligand- DNA-protein complex can be linked 
to inactivated adenovirus or fusogenic peptides that lysis endosomes 
(Curiel et aI., 1991; Wagner et aI., 1992). The production of high 
expression levels in vitro has been accomplished with this strategy using 
cultured hepatocytes. Recently, in vivo success using the strategy has also 
been demonstrated (Peralis et aI., 1994). Proteins that have been utilized 
for this approach include orosomucoid and transferrin, targeting the 
asialoglycoprotein receptor and transferrin receptor, respectively 
(Cristiano et aI., 1993; Wagner et aI., 1994; Frese et aI., 1994). Liposomes 
(FeIgner et aI., 1987; Frese et aI., 1994), direct injection of DNA (Wolff et 
aI., 1990) and pneumatically delivered DNA-coated gold particles (Yang 
et aI., 1990) have also been used to deliver DNA to the target cells. 
Successful somatic gene therapy depends not only on the molecular 
identification of a disease-related gene and the efficacy of gene transfer, 
but also on the understanding of the pathogenesis of the disease. For the 
lysosomal storage disease galactosialidosis as a good example, it was 
initially thought that this disease was a rare variant of B-galactosidase 
deficiency. Later an additional neuraminidase deficiency was observed in 
patients and ultimately it was demonstrated that this combined lysosomal 
enzyme deficiency was due to a primary defect in a third protein (D' Azzo 
et aI., 1995). 
Another important aspect that must be considered is the type of cells, 
tissues and organs that are most profoundly affected. If a transferred 
normal gene cannot reach the major target organs, therapy may be very 
inefficient. In lysosomal storage diseases passage through the blood-brain 
barrier may also present a major problem. 
In type 1 Gaucher disease, accumulation of glucocerebroside is mainly 
restricted to bone-marrow derived macrophages and this disease is a 
good candidate for somatic gene therapy. The observed beneficial 
response after allogenic BMT in patients with type 1 and type 3 Gaucher 
disease makes the transfer of the normal glucocerebrosidase gene by 
retroviral vectors into hematopoietic stem cells followed by autologous 
BMT an attractive approach to consider. 
Several groups have reported protein expression in macrophages 
differentiated from mouse hematopoietic stem cells that were infected 
with a retroviral vector containing the human glucocerebrosidase gene 
(Weinthal et aI., 1991; Ohashi et aI., 1992; Correll et aI., 1992; Krall et aI., 
1994). A retroviral vector based on the Moloney murine leukemia virus 
long terminal repeat has been effective (Freas-Lutz et aI., 1994). 
Immunohistochemical analysis of tissues of transplanted mice revealed 
that expression of human glucocerebrosidase was not only restricted to 
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macrophages in visceral tissues, but also in brain. In the central nervous 
system of these mice, human glucocerebrosidase-positive macrophages 
were observed, predominantly in perivascular spaces, but surprisingly 
also in microglia in close proximity with blood vessels. These findings 
suggest that circulating monocytes can enter the brain as perivascular 
cells and subsequently traverse the basement membrane and enter the 
brain parenchyma. The reconstitution with mouse glucocerebrosidase-
positive macrophages is however only partial i.e. on the average in 20% 
of the Kupffer cells, splenic macrophages and microglia cells by 8 months 
after transplantation (Krall et al., 1994). Long-term bone-marrow cultures 
of hematopoietic cells of Gaucher patients were also successfully 
transduced with a retroviral vector encoding normal glucocerebrosidase 
cDNA partially (30-50%) (Nolta et al., 1992; Xu et al., 1994). 
Similar observations were obtained in is-glucuronidase deficient mice in 
which the therapeutic gene (normal is-glucuronidase) was transferred into 
bone-marrow progenitors by either retrovirally mediated gene transfer 
(Wolfe et al., 1992a) or by herpesvirus vector gene transfer into the central 
nervous system (Wolfe et al., 1992b). In addition, retroviral transduction 
of the human is-glucuronidase cDNA into primary mouse skin fibroblasts 
which were engrafted into neo-organs in syngeneic recipient mice yielded 
engrafted fibroblasts expressing the human enzyme and resulted in a 
reduction of the lysosomal storage in these animals (Moullier et al., 1993). 
Thus, the secretion-recapture mechanism with low expression of vector-
transferred genes in vivo can result in partial correction of pathology. 
Prior to initiation of human clinical trials, the safety and efficacy of 
somatic gene therapy should be determined in appropriate animal 
models. Currently, most of the approved human protocols have focused 
on retroviral and adenoviral vectors to transfer genes into hepatocytes 
(OTC-deficiency, hypercholesterolemia), hematopoietic cells (ADA-
deficiency, Gaucher disease, cancer), lung (Cystic Fibrosis) and muscle 
(Duchenne type muscular dystrophy) (reviewed by Morsy et al., 1993; 
Correll and Karlsson, 1994). None of these somatic gene therapy attempts 
have led to a permanent correction of the enzyme/protein deficiencies. 
However, further development of highly efficient gene delivery systems 
that lead to permanent expression of stable and sufficient amounts of the 
gene product that are necessary to alleviate all clinical manifestations of 
the disorder will hopefully become available in the next decade, making 
somatic gene therapy a useful therapeutic option for heritable diseases. 
The correction or prevention of human genetic deficiences through the 
transfer of normal genes into reproductive cells (germ-line gene 
modification) is currently not possible. Even if the technical obstacles are 
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overcome many ethical questions remain to be resolved (Wivel and 
Walters, 1993). 
u.s. ANIMAL MODELS 
The availability of appropriate animal models of lysosomal storage 
disorders facilitates examination of the pathogenesis of the disease and 
the investigation of new experimental therapeutic strategies. Animal 
models for lysosomal storages diseases can be classified into three 
categories: 
1. Several spontaneously occurring lysosomal storage diseases in animals 
have been recognized and documented (Farrow et aI., 1980). 
2. Chemical induced animal models have been produced by admini-
stration of inhibitors of lysosomal enzymes. 
3. Gene-specific disruption in mice by gene-targeting in embryonic stern 
cells has resulted in "knock-out" or "null"-allele mice (reviewed by Doi 
et aI., 1992; Melton, 1994). These mice can provide an adequate model 
of the analogous human disease for studying the loss of specific gene 
function. 
In Table 2 the reported "knock-out" mouse models of lysosomal storage 
diseases are listed. More subtle gene alterations by introduction of specific 
point mutations by homologous recombination (hit and run method and 
double replacement method) have been devised to model a specific 
phenotype of the disease (Melton et aI., 1994). 
A naturally occurring canine model of Gaucher disease in the Australian 
Silkie Terrier had been reported but not propagated (Farrow et aI., 1982). 
Inhibition of glucocerebrosidase by conduritol B epoxide (CBE) in mice 
generated an animal model having the biochemical characteristics of 
Gaucher disease (Kanfer et aI., 1982). However, ultrastructurally, no 
Gaucher cells were observed in either the viscera or brain, although 
neurons displayed inclusion bodies similar to those seen in human 
Gaucher disease (Adachi and Yolk, 1977). Thus, inhibition of 
glucocerebrosidase by CBE has been inadequate in creating an animal 
model for Gaucher disease. 
Targeted disruption of the mouse glucocerebrosidase gene has resulted 
in a mouse model with a phenotype analogous to severely affected 
neonates with type 2 Gaucher disease (Sidransky et aI., 1992). 
Homozygous "null" allele mutant mice die within 24 hours after birth and 
have no residual enzyme activity, no detectable glucocerebrosidase cross-
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Table 2. Knock-out mice for lysosomal storage diseases 
Defective enzyme Disease Phenotype Reference 
or receptor analogue 
glucocerebrosidase Gaucher disease severe type 2 Tybulewicz et 
al.,1992 
CD-MPR ? normal KosIer el aI., 1993 
Ludwig et aI., 1993 
CI-MPR ? lethal at birth Wang et aI.. 1994 
aryslsulfatase B Mucopo1y- infantile Peters et aI.. 1994 
saccharidosis VI 
lysosomal acid ? ? Saftig et al.. 1994 
phosphatase 
cathepsin D ? ? Peters et aI., 1994 
cathepsin A Galactosialidosis infantile/juvenile d'Azzo et aI., 1994 
hexosaminidase A Tay-Sachs late-onset Yamanaka ct al., 1994 
arylsulfatase A Metachromatic normal Gieselmann 
leucodystrophy personal camm. 
?=corresponding disease not defined 
reactive material and store glucocerebroside in lysosomes of macrophages 
located in the mononuclear phagocyte system, microglia and in brainstem 
and spinal cord neurons (Tybulewicz et aI., 1992; Willemsen et aI., 1995). 
In addition, examination of the cellophane-like skin of these mice, showed 
severe disruption of the lamellar bilayer structure of the outer stratum 
corneum (Holleran et aI., 1994). The cause of the early and rapid demise 
of these Gaucher mice is unknown. At birth they are underweight and 
show feeding and respiratory complications. Surprisingly, the cellular 
pathology of tissues from these Gaucher mice was very mild, suggesting 
that a toxic metabolite may be responsible for their rapid postnatal 
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demise. It has been hypothesized that glucosylsphingosine, a neurotoxic 
metabolite, could disrupt neuronal activity by interfering with signal 
transduction and cellular differentiation. However, an incompetent 
epidermal barrier, dehydration and poor feeding, may all contribute to 
their early death (Willemsen et aI., 1995). 
Despite the many positive expectations for genetically produced animal 
models it is important to consider possible biochemical and cell biological 
differences between man and mice. This phenomenon is well illustrated 
by the mouse model for Lesch-Nyhan syndrome, an inherited neurologic 
disorder in man caused by hypo-xanthine-guanosine phosphoribosyl 
transferase (HPRT) deficiency. Despite the severe and characteristic 
clinical features in affected children the mouse model did not show any 
features of the characteristic human phenotype (Hooper et aI., 1987; 
Kuehn et aI., 1987). In this instance it has been shown that mice might be 
less dependent than man on HPRT in their cellular biochemical pathways 
(Wu and Melton, 1993). 
On the other hand, homozygous "knock-out" mutant mice have, however, 
provided new insights into the pathogenesis of the most severe form of 
Gaucher disease. A Gaucher mouse created by the introduction of specific 
missense mutations associated with milder presentations of Gaucher 
disease should provide a longer lived mouse with less severe symptoms. 
These mildly affected mice should be valuable for testing novel 
therapeutic strategies and for the study of the underlying pathogenetic 
mechanisms causing different clinical variants of Gaucher disease. 
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CHAPTER III 
THE EXPERIMENTAL WORK 

III.1. OBJECTIVES 
Gaucher disease is an inherited sphingolipid lysosomal storage disease 
caused by a deficiency of the lysosomal enzyme glucocerebrosidase. The 
clinical presentation of Gaucher disease varies considerably. The question 
is whether this is related to the more than 50 different mutations that have 
so far been found within the gene for glucocerebrosidase or whether 
epigenetic or environmental factors playa major role. To approach this 
question studies were performed on the biosynthesis, subcellular 
localization and function of normal and mutant enzyme, because these 
parameters determine primarily the capability of cells to catabolize 
glucocerebroside, the natural substrate of glucocerebrosidase. A second 
approach was to study an animal model for Gaucher disease, offering new 
perspectives for the examination and understanding of the pathogenesis. 
Animal models were employed in addition, to gather information on the 
fundamental mechanisms of existing therapies and to device novel 
experimental therapeutic strategies for Gaucher disease. The experimental 
work of this thesis is focused on these topics. 
III.2. RESULTS AND DISCUSSION 
Appendix paper I describes the ultrastructural localization of 
glucocerebrosidase in cultured skin fibroblasts from normal individuals 
and patients with the three types of Gaucher disease using the indirect 
irnrnunogold method on ultrathin frozen sections. We report the presence 
of glucocerebrosidase in different compartments of the biosynthetic 
pathway and demonstrate in vivo association of the enzyme with the 
lysosomal membrane. In fibroblast cell lines from 3 of the 4 patients with 
type 1 Gaucher disease not only was a similar localization pattern for 
glucocerebrosidase observed, but the intensity of lysosomal labelling was 
identical to that in controls. Biochemical characterization of the cell lines 
was established by Western blotting and enzyme activity assay. Three 
different molecular forms of glucocerebrosidase could be distinguished in 
cell homogenates of type 1 patients as in control cells, with molecular 
weights of 66 kDa, 63 kDa and 59 kDa (Erickson et aI., 1985). The 
membrane association was confirmed for the 66 kDa and 59 kDa 
molecular forms of glucocerebrosidase, using differential permeabilization 
of pulse-labelled HepG2 cells (Rijnboutt et aI., 1991). The near normal 
presence of all three molecular forms of glucocerebrosidase as detected by 
Western blotting and the low residual activity towards 4-MU-substrate in 
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these cell lines confirms the hypothesis that in type 1 Gaucher disease 
normal processing occurs, resulting in a lysosomal 59 kDa mature enzyme 
with a reduced catalytic activity (Ginns et aI., 1982 and 1983). 
In contrast, the mature 59 kDa molecular form of glucocerebrosidase was 
absent in fibroblasts from patients with type 2 and type 3 Gaucher disease 
which is indicative for a defect in the post-translational processing of the 
enzyme (Ginns et aI., 1982 and 1983; Beutler et aI., 1984). The absence of 
cross-reactive material in lysosomes of these mutant cells suggests that the 
59 kDa form of glucocerebrosidase is the lysosomal form. The observed 
normal labelling of RER and Golgi complex in type 2 and type 3 
fibroblasts is suggestive of either a rapid lysosomal degradation of the 
mutant enzyme, obstruction of transport followed by pre-lysosomal 
degradation or loss by secretion. The presence of mature enzyme in 
lysosomes of non-neuronopathic Gaucher patients, on the one hand, and 
the absence of mature enzyme in lysosomes of neuronopathic patients, on 
the other, has led us to speculate that the presence of sufficient residual 
glucocerebrosidase activity in type 1 disease precludes development of 
neurologic symptoms. This principle of a "critical threshold" for lysosomal 
storage diseases was suggested by Conzelmann and Sandhoff (1983), and 
it might explain how differences in residual activity within lysosomes can 
influence the clinical presentation of the disease to a great extent. 
In appendix paper II the combined technologies of irnmunoelectron-
microscopy and biochemistry are applied to study the lipid-loaden 
Gaucher cells in the spleen from a patient with type 1 Gaucher disease, 
because these cells are the primary site of glucocerebroside storage. The 
specific activity of glucocerebrosidase in splenic extracts from normal 
individuals and the type 1. patient was determined by measuring 
glucocerebrosidase activity towards 4-MU-substrate and the molecular 
forms were identified by Western blotting. In splenic extracts from the 
type 1 patient a significantly reduced (20X) activity was measured. 
Western blot analyses revealed three molecular forms of 66 kDa, 63 kDa 
and 59 kDa with similar intensity for both control spleen extracts and 
extracts of the type 1 patient. These results suggest a decreased activity 
per molecule of glucocerebrosidase (specific activity) in the spleen from 
this type 1 patient and thereby confirm the results obtained with 
fibroblasts as described in appendix paper 1. 
Subcellular localization was studied by performing irnmunoelectron-
microscopy on ultrathin frozen sections of the spleen tissue using 
polyclonal antibodies against glucocerebrosidase. The enzyme was present 
in the characteristic lipid-loaden Gaucher cells. Since the storage material 
in the lysosomes of these Gaucher cells was well preserved it could be 
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demonstrated that the enzyme was associated with the twisted glycolipid 
tubules within the lysosomes. Thus, mutant enzyme is targeted correctly 
to lysosomes of Gaucher cells in the spleen of this type 1 patient, however, 
the enzyme is catalytically defective. Co-localization with other lysosomal 
enzymes in double labelling experiments, using gold particles of different 
sizes (5 and 10 nm) supported the view that glucocerebroside does not 
accumulate in specific storage lysosomes that have lost their normal 
function. 
The experimental work on the "knock-out" Gaucher mouse in the 
appendix papers III and IV has enabled us to study the cell biology and 
ultrastructural pathology of severe type 2 Gaucher disease in more detail 
than possible with human patients. This animal model of type 2 Gaucher 
disease was generated by targeted disruption of the mouse 
glucocerebrosidase gene in embryonic stem (ES) cells through homologous 
recombination. These genetically modified ES cells were used to generate 
a mouse strain homozygous for a null glucocerebrosidase allele. 
The type 2 Gaucher mouse, had a striking and rapidly deteriorating 
phenotype resulting in death within 24 hours after birth. Some 
characteristic features were: feeding and movement difficulties, abnormal 
respiration and a cellophane-like appearance of the skin. Homozygous 
mutant mice had no residual glucocerebrosidase activity towards 4-MU-
substrate and thin-layer chromatography revealed elevated glucocere-
broside levels in liver, lung and brain tissue. Western blot analyses of 
brain and liver tissue from homozygous mutant mice showed absence of 
glucocerebrosidase protein, whereas Western blot analyses of tissue from 
normal and heterozygous littermates showed a major molecular form with 
an apparent molecular weight of 56 kDa. Surprisingly, the cellular 
pathology of tissues from these homozygous mutant mice was very mild. 
Ultrastructural studies of tissues from the type 2 Gaucher mouse revealed 
the characteristic twisted tubular structures of accumulated 
glucocerebroside within lysosomes of macrophages from liver, brain, 
bone-marrow and spleen, although typical Gaucher cells, the hallmark of 
Gaucher disease, were not observed by light-microscopy. Co-localization 
with both ingested carbon particles and cathepsin D confirmed the 
lysosomal nature of these storage vacuoles. No lipid accumulation was 
found in macrophages from normal or heterozygous mouse litter mates. 
Electronmicroscopic study of central nervous system neurons revealed the 
presence of stored glucocerebroside in brainstem and spinal cord neurons, 
but absence of glucocerebroside storage in neurons of the cerebellum and 
cortex. A similar lipid storage pattern is observed in type 2 human 
Gaucher patients (Banker et aI., 1962) and suggests varying 
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glycosphingolipid catabolism within different brain regions. The rapid 
demise of these newborn mutant mice is intriguing and several causes 
were proposed as discussed below. 
Despite the rapid deterioration of the type 2 Gaucher mice the cellular 
pathology of liver, spleen, bone marrow and the central nervous system 
was very mild. Most neurons did not show lipid storage and only a very 
limited quantity of stored glucocerebroside was found in certain groups 
of neurons. These results suggest that a neurotoxic metabolite, such as 
glucosylsphingosine, may contribute to the early and rapid demise of the 
type 2 Gaucher mice. This would suggest that neuronal dysfunction 
appears before gross cellular pathology is observable. In the brain of type 
2 patients elevated levels of glucosylsphingosine were recorded (Nilsson 
and Svennerholm, 1982). Recently, it has been postulated that lyso-
sphingolipids, such as glucosylsphingosine, are potent inhibitors of 
protein kinase C activity, even at low concentrations (Hannun and Bell, 
1987). Hence they could interfere with signal transduction and cellular 
differentiation and disrupt neuronal activity. Similarly, a correlation was 
found between the concentration of galactosylsphingosine in the brain of 
the twitcher mouse, a murine analogue of Krabbe's disease, and the 
observed pathology. Tissues containing higher concentrations of galacto-
sylsphingosine show earlier and more severe pathological changes 
(Shinoda et al., 1987). 
Recent studies with a conduritol B epoxide induced animal model of 
Gaucher disease have demonstrated an important role for gluco-
cerebrosidase in the epidermal permeability barrier function (Holleran et 
aI., 1993). Lipids enriched in ceramides, which are localized in the 
intercellular spaces of the stratum corneum, are critical components in 
epidermal permeability barrier function. Conversion of glucocerebroside 
to ceramide is essential to form normal intercellular membrane structures. 
Thus, absence of glucocerebrosidase activity in the epidermis results in an 
incorrect processing of epidermal glucocerebroside and as a consequence 
an abnormal epidermal permeability barrier function. The skin abnor-
malities observed in the type 2 Gaucher mice is attributed to abnormal 
intracellular lamellar bilayers as a result of deficient glucocerebrosidase 
activity (Holleran et aI., 1994). This disruption of the skin barrier may also 
contribute to the rapid demise of the type 2 Gaucher mice. In addition, 
these observations in mice led to the appreciation of a subset of neonates 
that were initially diagnosed with an collodion-like skin and/ or hydrops 
fetalis (Sidransky et aI., 1992). Newborn homozygous mutant mice were 
frequently separated from the nest and ignored by their mothers. This 
ejection resulted in a lack of feeding of these mutant mice. Therefore, 
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dehydration and hypoglycemia may also contribute to the observed rapid 
deterioration. 
A mouse model of Gaucher disease should be a valuable tool to 
investigate the potential effect of currently applied and newly developed 
therapeutic interventions. Unfortunately, the short-lived mice described in 
appendix paper III and IV have very limited use for evaluating 
therapeutic strategies for Gaucher disease. Generation of mouse strains 
with specific point mutations, associated with a milder presentation of the 
disease, should produce longer lived mice and thus permit development 
of successful therapeutic interventions. 
Successful enzyme replacement therapy with modified human placental 
glucocerebrosidase (alglucerase, Ceredase™) in patients with type 1 
Gaucher disease has been developed. The strategy of alglucerase 
administration is based on the modification of the carbohydrate chains of 
glucocerebrosidase by exoglycosidases into terminal mannose residues, 
mediating efficient delivery to macrophages via the mannose receptor 
system (Furbish et aI., 1981; Brady et aI., 1994). However, the dose 
regimen and clinical efficacy is still controversial. The work reported in 
appendix paper V involves the characterization of enzyme replacement 
therapy in Gaucher disease in normal mice. In this study the biochemical 
identification, targeting and intracellular trafficking in mice of 
intravenously infused human unmodified glucocerebrosidase and 
alglucerase (60 IU/kg body weight) were determined in the absence or 
presence of mannan. Immunoprecipitation studies, using monoclonal 
antibodies against human glucocerebrosidase enabled discrimination 
between mouse (endogenous) and human enzyme (Barneveld et aI., 1983). 
We observed a significant increase of human glucocerebrosidase activity 
towards 4-MU-substrate in liver and spleen tissue with a highest activity 
at 15 minutes after administration of alglucerase. 
This targeting to liver and spleen tissue occurs through mannOse receptor-
mediated binding as was demonstrated by simultaneous administration 
of mannan to the infusion sample, resulting in dramatically less 
immunoprecipitable glucocerebrosidase activity in both organs. The 
targeting of alglucerase to liver tissue was almost three fold higher 
compared to the targeting of alglucerase to spleen tissue at 15 minutes 
after administration. Characterization of the molecular forms of 
alglucerase in both liver and spleen tissue homogenates by 
immunoprecipitation followed by Western blotting, revealed one band of 
cross-reactive material of approximately 60 kDa. This form was decreased 
in intensity when mannan was infused simultaneously. These data 
illustrate the presence of mature, active glucocerebrosidase in liver and 
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spleen tissue following alglucerase infusion. 
The targeting of alglucerase in liver was visualized by light- and 
electronmicroscopic techniques, using rabbit polyclonal antibodies against 
human placental glucocerebrosidase. For light-microscopy we applied the 
indirect immuno-peroxidase technique on cryostat sections and for 
immunoelectronmicroscopy we used the indirect immunogold method on 
ultrathin frozen sections. Cross reactivity of the antibodies with 
endogenous mouse glucocerebrosidase in liver sections was negligible. At 
the light-microscopic level a strong labelling in Kupffer cells and along the 
lining of the sinusoids was observed. It is clear that Kupffer cells are not 
the only target cells for alglucerase. Uptake inhibition with mannan 
suggests a mannose receptor mediated binding and uptake in both 
Kupffer cells and the endothelial cells lining the sinusoids. At the 
subcellular level, alglucerase was targeted to the endosomal/lysosomal 
system of both Kupffer cells and endothelial cells. 
These results confirm the biochemical findings in rats that showed an 
eight-fold increase in the delivery of glucocerebrosidase to non-
parenchymal cells after modification of the carbohydrate chains to expose 
terminal mannose residues (Furbish et aI., 1981). However, in these studies 
no discrimination was made between Kupffer cells and endothelial cells. 
Our in vivo results document that alglucerase is directed to both 
endothelial and Kupffer cells. Approximately two-thirds of the non-
parenchymal liver cells are endothelial cells and the fact that sinusoidal 
endothelial cells are the most active in binding and internalizing of 
mannose-terrninated ligands (Hubbard et aI., 1979; Stang et al., 1990) 
suggest that the majority of alglucerase is directed to endothelial cells, 
rather than the intended Kupffer cells. Recently, similar findings were 
reported in vitro, using cultured macrophages and cultured endothelial 
cells (Sato and Beutler, 1993). 
Our study would suggest that the cellular mechanisms responsible for 
clinical improvement following alglucerase treatment of patients with 
Gaucher disease, may be more complex than previously recognized. 
Further studies using a mouse model with type 1 Gaucher disease created 
by introduction of a "mild" mutation (like the N370S mutation) into the 
murine glucocerebrosidase gene, should produce longer-lived mice with 
accumulation of glucocerebroside in Gaucher cells. The opportunity to 
perform further biochemical and immunoelectron microscopic studies in 
these mice, and to especially be able to study the uptake of administered 
enzyme in Gaucher cells, should provide better insights into the cellular 
mechanisms responsible for efficacy of enzyme replacement therapy in 
patients with Gaucher disease. 
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SUMMARY 
The human body is composed of some few hundred different cell types, 
which are integrated into tissues and organs. Individual cells consist of 
distinct cellular compartments separated by membranous partitions, like 
the nucleus, mitochondria, lysosomes, Golgi complex and endoplasmic 
reticulum. Many cell functions depend upon the interaction between 
different compartments and a proper metabolic processing within these 
compartments. 
Lysosomes are membrane-enclosed acidic vesicles that playa major role 
in the degradation of a variety of extracellular and intracellular 
macromolecules. The intralysosomal catabolism of substrates is catalysed 
by lysosomal enzymes (hydrolases). Some human genetic disorders are 
known to be the result of a deficient function of one or more lysosomal 
proteins. The more than thirty lysosomal storage disorders known today 
are based either on a deficiency or dysfunction of a lysosomal enzyme, 
a lysosomal activatorprotein or are due to a defective lysosomal 
membrane transport system. The intralysosomal accumulation of 
(macromolecular) degradation products is a characteristic phenomenon 
and affects the function of specific cell types and organs. An overview on 
lysosomal storage disorders and the functioning of the lysosomal system 
is provided in Chapter I. 
Gaucher disease is the most common lysosomal storage disorder and is 
caused by a deficiency of glucocerebrosidase. At present over 50 different 
mutations have been identified in the gene encoding glucocerebrosidase. 
Some of the mutations are common others are rare. Patients can be 
homozygous for one particular mutation, but most patients have different 
mutations in each of their two alleles (compound heterozygosity). The 
stored compound in Gaucher disease is glucocerebroside, which is mainly 
found in cells of the mononuclear phagocyte system. They have a 
characteristic morphology and are named "Gaucher cells". The clinical 
phenotype of Gaucher disease is very heterogeneous, ranging from 
asymptomatic or mildly affected adult patients to children who die after 
a severe clinical course. Patients without neurologic involvement are 
classified as type 1, whereas patients with neurologic involvement are 
classified as type 2 (acute) or type 3 (subacute). Only recently has thera-
peutic intervention (enzyme replacement therapy) by intravenous 
administration of modified glucocerebrosidase (Alglucerase, Ceredase™) 
become effective, albeit only for patients with type 1 Gaucher disease. A 
historical perspective of Gaucher disease, related research and future 
prospects are given in Chapter II. 
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Immunoelectron microscopy was one of the major tools in the experi-
mental work described in this thesis (Chapter III), which was aimed at 
understanding the cause of clinical heterogeneity in Gaucher disease by 
delineating more precisely the nature of glucocerebrosidase deficiency 
with respect to the biosynthesis, the subcellular location and function of 
the mutant glucocerebrosidase. The results of these studies are presented 
in appendix papers I and II. 
A second aim was to gain further insight into the pathogenesis of the 
disease. To this end a mouse model of Gaucher disease type 2 was 
studied. This "Gaucher mouse" was generated by creating a null 
glucocerebrosidase allele in embryonic stem cells through homologous 
recombination (knock-out mouse). The homozygous mutant mice are the 
first example of a mouse model of a human inherited metabolic disease 
produced using this technology. Appendix paper III reports on the 
technological details of the targeted mutagenesis of this mouse gene, 
documents the glucocerebrosidase deficiency in the homozygous mutant 
mouse, and illustrates the storage of glucocerebroside in Kupffer cells of 
the liver and macrophages in the bone marrow. A more detailed 
investigation into the distribution of lysosomal storage in the liver, spleen, 
bone marrow and in different parts of the central nervous system follows 
in appendix paper IV. The paradox of early lethality and minor 
morphological changes in our mouse model raises questions concerning 
the pathogenic mechanisms. 
The mechanism by which enzyme replacement therapy is thought to 
result in a beneficial effect is addressed in appendix paper V using a 
normal mouse model. 
In the small series of patients investigated in appendix paper I and II the 
clinical phenotype of Gaucher disease correlates with the molecular 
phenotype of mutant glucocerebrosidase. In patients with the mildest 
form of the disease (type 1), cells synthesize a normal amount of 
glucocerebrosidase, which matures normally and associates with the 
lysosomal membrane. It lacks however activity to catabolize the substrate 
at a rate sufficient to prevent storage and clinical symptoms. In patients 
with the more severely affected forms of Gaucher disease (type 2 and 
type 3) a defect in maturation and a marked deficiency of lysosomal 
glucocerebrosidase is observed. These findings led us to speculate that 
sufficient residual glucocerebrosidase activity within lysosomes of 
neurons of type 1 patients prevents lysosomal storage and consequently 
precludes neurologic symptoms. 
The mouse model of human Gaucher disease type 2, as described in 
appendix papers III and IV, revealed pathological features that earlier on 
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were not associated with the acute form of Gaucher disease in man. The 
cellular pathology of the mouse, however, appeared unexpectedly mild. 
Typical Gaucher cells were not identified. Lysosomal storage of 
glucocerebroside in the central nervous system was localized in microglia 
(macrophages) and was observed only sporadically in certain neurons. 
These findings could not explain the rapid demise of the Gaucher mouse 
24 hours after birth. It was therefore hypothesized that death is the result 
of a neurotoxic metabolite. 
The study of enzyme replacement therapy in mice, as reported in 
appendix paper V, illustrates that at least a portion of the mannose-
terminated human placental glucocerebrosidase (Ceredase™) is taken up 
by Kupffer cells via the mannose receptor system and is delivered to the 
lysosomal system. However, our study also demonstrates the potential 
"loss" of enzyme by uptake by hepatic endothelial cells lining the blood 
sinusoids. It may well be that uptake of Ceredase™ by these endothelial 
cells contributes to the therapeutic effect by clearing the blood plasma of 
glucocerebroside. Genetic mouse models, representing the different" 
clinical phenotypes of human Gaucher disease, are presently under 
development and they should provide a means to study the pathogenic 
mechanisms and to test novel therapeutic strategies. 
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SAMENV A TIING 
Het menselijk lichaam is opgebouwd uit enige honderden verschillende 
celtypen, die geintegreerd zijn in weefsels en organen. Individuele cellen 
bevatten afzonderlijke compartimenten die begrensd zijn door een 
membraan zoals de kern, mitochondria, lysosomen, het Golgi complex en 
het endoplasmatisch reticulum. Veel celfuncties zijn afuankelijk van de 
samenwerking tussen de verschillende compartimenten en van correcte 
metabole processen in deze compartimenten. 
Lysosomen zijn compartimenten met een hoge zuurgraad. Zij spelen een 
belangrijke rol bij de afbraak van een groot aantal extracellulaire en 
intracellulaire macromoleculen. De intralysosomale afbraak van substraten 
wordt gekatalyseerd door Iysosomale enzymen (hydrolasen). Een aantal 
genetische ziekten wordt veroorzaakt door een functioneel verlies van een 
of meerdere lysosomale eiwitten, hetgeen leidt tot accumulatie (stapeling) 
van bepaalde moleculen in de lysosomen. Momenteel zijn bij de mens 
meer dan dertig lysosomale stapelingsziekten bekend. Zij zijn gebaseerd 
op een deficientie of dysfunctie van een lysosomaal enzym of een 
lysosomaal activatoreiwit, of zij worden veroorzaakt door een defect in 
het transportsysteem in de lysosomale membraan. De intralysosomale 
stapeling van (macromoleculaire) afbraakprodukten is een karakteristiek 
fenomeen en beinvloedt de functie van specifieke celtypen en organen. 
Informatie over het functioneren van het lysosomale systeem en een 
overzicht van lysosomale stapelingsziekten wordt gegeven in Hoofdstuk 
1. 
De ziekte van Gaucher is de meest voorkomende lysosomale stapelings-
ziekte en wordt veroorzaakt door een deficientie van glucocerebrosidase. 
Tot op heden zijn 50 verschillende mutaties in het gen dat codeert voor 
glucocerebrosidase gevonden. Sommige mutaties komen vaak voor, 
andere zijn zeldzaam. Patienten kunnen homozygoot voor een bepaalde 
mutatie zijn, maar de meeste patienten hebben verschillende mutaties in 
de twee copieen van het glucocerebrosidase gen. Het gestapelde produkt 
bij de ziekte van Gaucher is glucocerebroside dat voornamelijk gevonden 
wordt in cellen van het mononucleaire fagocytensysteem. De afwijkende 
cellen hebben een karakteristieke morfologie en worden "Gaucher cellen" 
genoemd. Het klinisch fenotype van de ziekte van Gaucher is erg 
heterogeen en varieert van mild aangedane volwassen patienten tot 
kinderen die overlijden na een ernstig klinisch verloop. Patienten zonder 
neurologische afwijkingen worden aangeduid als type 1, terwijl patienten 
met neurologische afwijkingen aangeduid worden als type 2 (acuut) of 
type 3 (subacuut). Sinds kort is therapeutische interventie 
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(enzymvervangingstherapie) door middel van intraveneuze toediening 
van gemodificeerd glucocerebrosidase effectief gebleken, echter aileen 
voor patienten met de type 1 vorm van de ziekte van Gaucher. In 
hoofdstukII wordt een historisch overzicht van de ziekte van Gaucher 
gegeven, gerelateerd onderzoek wordt vermeld en toekomstige 
verwachtingen worden bediscussieerd. 
Het experimentele werk, beschreven in dit proefschrift, is voornamelijk 
gebaseerd op immunoelectronenmicroscopie. Dit onderzoek had als doel 
de oorzaken van klinische heterogeniteit nader te bestuderen. Speciale 
aandacht werd besteed aan de biosynthese, de subcellulaire locatie en de 
functie van het normale en het gemuteerde glucocerebrosidase. De 
resultaten van deze studies zijn beschreven in appendix papers I en II. 
Een tweede doelstelling was om meer inzicht te verkrijgen in de 
pathogenese van de ziekte. Hiertoe werd een muismodel v~~r de ziekte 
van Gaucher type 2 bestudeerd. Deze "Gaucher muis" werd verkregen 
door het glucocerebrosidase gen van de muis uit te schakelen via 
homologe recombinatie in embryonale stamcellen ("knock-out" 
technologie). De Gaucher muizen zijn het eerste voorbeeld van een 
succesvolle . poging om een muismodel van een humane erfelijke 
stofwisselingsziekte op deze wijze te verkrijgen. Appendix paper III 
beschrijft de technische details van de procedure, documenteert de 
glucocerebrosidase deficientie in de homozygoot mutante muis en laat de 
stapeling van glucocerebroside in Kupffer cellen in de lever en 
macrofagen in het beenmerg zien. Een meer gedetailleerd onderzoek naar 
het voorkomen van Iysosomale stapeling in de lever, milt, beenmerg en 
in verschillende delen van het centraal zenuwstelsel van de Gaucher muis 
voIgt in appendix paper IV. De tegenstelling tussen vroege dood en 
geringe morfologische veranderingen in oris muismodel roept vragen op 
ten aanzien van het pathogenetische mechanisme. 
Het mechanisme van enzymvervangingstherapie wordt beschreven in 
appendix paper V. Hierbij werd gebruik gemaakt van een normaal 
muismodel. 
Met de kleine aantallen patienten, die bestudeerd zijn in appendix paper 
I en II werd een correlatie gevonden tussen het klinische fenotype van de 
ziekte van Gaucher en het moleculaire fenotype van het gemuteerde 
glucocerebrosidase. Cellen van patienten met de mildere vorm van de. 
ziekte (type 1) synthetiseren een normale hoeveelheid glucocerebrosidase. 
De enzym precursor ondergaat de normale post-translationele 
veranderingen en bereikt het Iysosoom, waar het geassocieerd is met de 
Iysosomale membraan. De activiteit van het mutante enzym is echter 
onvoldoende om het substraat in die mate' af te breken dat stapeling en 
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klinische symptomen worden voorkomen. Bij patienten aangedaan met 
de meer ernstige vormen van de ziekte van Gaucher (type 2 en type 3) 
wordt een verstoring van de maturatie en een duidelijke deficientie van 
het lysosomale glucocerebrosidase gevonden. Deze resultaten hebben 
geleid tot de speculatie dat er bij Gaucher type 1 voldoende restactiviteit 
van het glucocerebrosidase is om lysosomale stapeling in neuronen en 
daarmee neurologische symptomen te voorkomen. 
Het muismodel van de humane ziekte van Gaucher type 2, zoals 
beschreven in appendix paper III en IV, leverde pathologische beelden op 
die eerder niet geassocieerd werden met de acute vorm van de ziekte van 
Gaucher bij de mens. De cellula ire pathologie van de muis bleek 
onverwacht mild. Typische Gaucher cellen werden niet gevonden. 
Lysosomale stapeling van glucocerebroside in het centrale zenuwstelsel 
werd in microglia gelocalizeerd en werd slechts zelden in bepaalde 
neuronen waargenomen. Deze resultaten konden de snelle dood van de 
Gaucher muis, binnen 24 uur na de geboorte, niet verklaren. Er wordt 
daarom verondersteld dat de dood veroorzaakt wordt door een 
neurotoxisch stofwisselingsproduct. 
De studie naar het mechanisme van enzymvervangingstherapie bij 
muizen, zoals beschreven in appendix paper V, illustreert dat tenrninste 
een deel van het toegediende gemodificeerde humane glucocerebrosidase 
(Ceredase™) via de mannose receptor opgenomen wordt door Kupffer 
cellen en vervolgens getransporteerd wordt naar het lysosomale systeem. 
Echter, onze studies tonen ook het potentiele "verlies" van enzym aan, 
door opname in lever endotheel cellen gelegen langs de bloed sinusoiden. 
Anderzijds zou opname van Ceredase™ door deze endotheelcellen 
kunnen bijdragen aan het therapeutische effect door het verwijderen van 
glucocerebroside uit het bloedplasma. Genetisch gemodificeerde muizen, 
die de verschillende klinische fenotypen van de humane ziekte van 
Gaucher vertegenwoordigen zijn momenteel in ontwikkeling en deze 
maken het mogelijk de pathogenetische mechanismen nader te bestuderen 
en nieuwe therapeutische strategieen uit te testen. 
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ABBREVIATIONS 
AA V adeno associated virus 
ADA adenosine deaminase 
Asn asparagine 
ATP adenosine triphosphate 
BHK baby hamster kidney 
BMT bone marrow transplantation 
CBE conduritol B epoxide 
CD-MPR cation dependent mannose 6-phosphate receptor 
cDNA complementary DNA 
CHO chinese hamster ovary 
CI-MPR cation independent mannose 6-phosphate receptor 
DNA desoxyribonucleic acid 
EGF epidermal growth factor 
ER endoplasmic reticulum 
ES embryonic stem 
GERL Golgi-endoplasmic reticulum-Iysosomes 
GLUT glucose transporter 
HA hydroxyl-apatite 
HPRT hypo-xanthine-guanosine phosphoribosyl transferase 
Ig immunoglobulin 
kB kilo base 
kDa kilo dalton 
LDL low density lipoprotein 
Igp lysosomal membrane glycoprotein 
MDCK Madin-Darby canine kidney 
MPR mannose 6-phosphate receptor 
mRNA messenger ribonucleic acid 
NAC nascent-polypeptide-associated complex 
OTC ornithine transcarbamylase 
PDGF platelet derived growth factor 
PEG polyethylene glycol 
RER rough endoplasmic reticulum 
SAP sphingolipid activator protein 
SCID severe combined immunodeficiency 
Sf Spodoptera frugiperda 
TGN trans Golgi-network 
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ULTRASTRUCTURAL l.OCALIZATION OF Gl.UCO-
CEREBROSIDASE IN CULTURED GAUCHER'S DISEASE 
FIBROBLASTS BY IMMUNOCYTOCHEMISTRY 
R. Willemsen, J.M. van Dongen, E.I. Ginns, H.J. Sips, AW. Schram, J.M. 
Tager, J.A Barranger, AJ.J. Reuser. 
ABSTRACT 
The subcellular localization of glucocerebrosidase was studied in cultured 
skin fibroblasts from eight patients with Gaucher's disease. The enzyme, 
in situ, was visualized under the electron microscope by incubating 
ultrathin frozen sections of fibroblasts with antibodies against 
glucocerebrosidase, followed by a second incubation with goat anti-(rabbit 
IgG) coupled to colloidal gold. In control cells, most of the gold label was 
found in lysosomes, associated with the membrane. Labeling of the rough 
endoplasmic reticulum (RER) and Golgi complex was also observed. In 
fibroblasts from three Gaucher's disease patients without neurological 
symptoms (type 1 disease), a near normal amount of cross-reactive 
material (CRM) was detected in lysosomes, but in a fourth such patient, 
the lysosomal CRM was reduced. Little lysosomal glucocerebrosidase was 
detected in ceils from patients with the acute neuronopathic form (Type 
2) or the subacute neuronopathic form (Type 3) of Gaucher's disease. 
CRM in lysosomes correlates with amount of mature, 59 kDa 
glucocerebrosidase which is undetectable in type 2 and type 3 Gaucher's 
disease cell lines. These findings demonstrate that different mutations in 
the gene for glucocerebrosidase result in mutant proteins that have 
different intracellular localization. They also suggest that there is a 
relationship between the amount of cross-reactive material in the 
lysosomes and the phenotypic expression of the disease. 
INTRODUCTION 
An inherited deficiency of glucocerebrosidase in Gaucher's disease leads 
to accumulation of glucosy1ceramide in reticuloendothelial cells of various 
organs and tissues?,15. The clinical presentation of Gaucher'S disease 
varies considerably and has led to classification of patients into three 
subtypes or phenotypes. Type 1 (chronic, non-neuronopathic) is the most 
common with an estimated carrier frequency of 1 in 13 among Ashkenazi 
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Jews." Storage of glucosy1ceramide in this form of Gaucher's disease is 
restricted to the viscera and perivascular space in brain and is not 
observed within the brain parenchyma.' Type 2 (acute, neuronopathic) 
and type 3 (subacute, neuronopathic) Gaucher's disease are distinct from 
type 1, in that there is also involvement of the central nervous system. In 
type 3, signs of neurological damage appear later than in type 2.3 
Polymorphism of the enzyme protein has permitted discrimination of the 
different phenotypes.'·1o In brain and cultured fibroblasts from control 
subjects, three different molecular species of glucocerebrosidase are 
recognized immunochemically on Western blots. These represent 
biosynthetic forms of the enzyme.59 In type 1 Gaucher's disease all three 
molecular forms are present, whereas the mature form of the enzyme is 
characteristically deficient in phenotypes 2 and 39 Using a monoclonal 
antibody 8E4, a distinction between type 2 (cross reactive material absent) 
and type 3 (cross reactive material present) can be made.lO 
Since the mature forms of most lysosomal enzymes are derived from their 
precursor after extensive modification, the apparent absence of mature 
glucocerebrosidase in type 2 and type 3 Gaucher's disease could reflect 
improper processing and/or routing of the mutant enzyme 9 It is 
conceivable that the degree of maturation of a mutant enzyme and the 
cellular compartmentation together determine the capability of cells to 
catabolize glucosylceramide. We have now studied the subcellular 
localization of glucocerebrosidase in cultured skin fibroblasts of the three 
Gaucher's disease phenotypes using in,munocytochemical methods. 
MATERIALS AND METHODS 
Cell lines and culture conditions 
Fibroblast cell lines 83RD257, 543LAD, TRI, GRA and 8lRD238 were 
provided by Prof. M.F. Niermeijer, Department of Clinical Genetics, 
University Hospital, Rotterdam, The Netherlands. Dr. M.T. Zabot and Dr. 
M. Mathieu, Hospital Debrousse, Lyon, France, supplied cell line 01674S. 
The cell lines DMN 83.102, 5519, PRW and JF83AD were started from 
skin biopsy specimens taken by Dr. E. Ginns and Dr. J.A. Barranger from 
the Molecular and Medical Genetics Section, National Institutes of Health, 
Bethesda, USA. Cell line GM877 was obtained from the Human Mutant 
Cell Repository (Institute for Medical Research), Camden, New Jersey, 
USA. Early passages of each cell line were grown in Dulbecco's Modified 
Eagles Medium supplemented with 10% fetal calf serum and antibiotics 
(penicillin, 120 IU/ml and streptomycin, 0.12 mg/ml). 
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Immul1ocytochemistnj 
Immunocytochemistry was performed with affinity-purified rabbit 
polyclonal antibodies against homogeneous human placental glucocere-
brosidase.' For light microscopy, the fibroblasts were grown on coverslips, 
fixed, and then incubated with antibodies exactly as described 
previously.19 The indirect immunocytochemical procedure was performed 
with goat anti-(rabbit IgG) conjugated to fluorescein isothiocyanate 
(Nordic, Tilburg, The Netherlands) for the second step, as described by 
Van Dongen et al.19 
For ultrastructural studies, confluent cultures were harvested with trypsin 
and washed twice with fresh medium containing 10% fetal calf serum. 
The cells were resuspended in fresh medium and kept in a rotating tube 
for 2 h at 37°C to recover from possible typsinization damage. They were 
then collected from suspension by centrifugation and taken up in 0.1 M 
phosphate buffer (PB), pH 7.3, containing 1% acrolein and 0.4% 
glutaraldehyde. After fixation for 60 min at 4°C, the cells were rinsed 
twice in 0.1 M PB and resuspended in the same buffer containing 10% 
gelatin, at 37°C. The cells were directly pelleted and solidified on ice. The 
same fixative was used for postfixation to cross-link the gelatin, and the 
pellet was stored at 4°C in 0.1 M PB containing 1% paraformaldehyde 
and 1 M sucrose? Frozen sections were made as described by Tokuyasu16 
using a LKB III ultra microtome equipped with the 14800 cryokit. 
The methods used for immunocytochemistry were those described by 
Geuze et al.8 with the following minor modifications. Prior to incubation 
with the first antibody, the sections were treated for 10 min. with sodium 
borohydride (2 mg/ml PB) to reduce residual aldehyde groups of the 
fixative,,·2o Antigen-antibody complexes were visualized through binding 
of goat anti-(rabbit IgG) coupled to 10 nm colloidal gold 
(Janssen-Pharmaceutica, Belgium). After these incubations, the sections 
were stained as described by Tokuyasu17 and embedded in 1.5% 
methylcellulose." They were studied with a Phillips EM 400 at 80 KV. 
ImmUl1oblotting 
Proteins were separated in 10% polyacrylamide gels in the presence of 
sodium dodecylsulphate as described by Laemm1i'4 , transferred to 
nitrocellulose filters18, and then incubated with rabbit 
anti-glucocerebrosidase immunoglobulins. Immune complexes were 
detected using goat anti-(rabbit IgG) coupled to horse radish peroxidase 
(Biorad), according the manufacturers instructions. 
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Table 1. Some characteristic data on cell lines of healthy individuals and patients 
with Gaucher's disease 
Code Pheno- Glucocere- Glucosidase Blotting 
type brosidase xlO' pattern 
activity~ Hexosaminidase 
(nmol/h/ mg) 66 63 59 
GRA Normal 275 109 + + + 
84·1Z0133 Normal 396 160 + + + 
FC Normal 180 71 + + + 
81RD238 Normal 318 126 + + + 
5519 Type 1 12 4 + + + 
543LAD Type 1 13 5 + + + 
PRW Type 1 22 4 + + + 
83RD257 Type 1 8 2 + + + 
DMN Type 2 5 2 + 
GM877 Type 2 10 3 + + 
JF83AD Type 3 20 9 + 
016745 Type 3 50 7 + 
'Mean value of three assays 
Biochemical assays 
Glucocerebrosidase activity in fibroblast homogenates was assayed with 
4-methylumbelliferyl-B-D-glucoside in a reaction mixture (final volume, 
1 ml) containing 5mM substrate, O.l°,{, (w Iv) Triton X-lOO, 0.2% (w Iv) 
sodium taurocholate, 100 mM citrate-phosphate buffer (pH 5.2) and 
fibroblast homogenate. The N-acetyl-B-D-hexosaminidase activity was 
assayed as described by Galjaard6 
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RESULTS 
Fibroblast cell lines were used from patients who had been classified on 
the basis of clinical characteristics as having type 1, 2 or 3 Gaucher's 
disease (Table 1). To characterize the cell lines, cell extracts were prepared 
and molecular forms of glucocerebrosidase were separated in 
SDS-polyacrylamide gels. Proteins were subsequently transferred to a 
nitrocellulose filter and glucocerebrosidase was visualized 
immunochemically. The results are illustrated in Fig. 1. There are 3 bands 
type 1 type 2 type 3 
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Figure 1: Molecular forms of glucocerebrosidase in normal and mutant fibroblasts as 
revealed by immunoblotting. 
of cross reactive material in control fibroblasts with apparent molecular 
weights of 66 kDa, 63 kDa and 59 kDa. These bands correspond to the 
molecular species of 63 kDa, 61 kDa an 56 kDa, respectively, which were 
described previously by Ginns et al. using a slightly different gel 
system yo The band at about 72 kDa (see arrows) is contaminating protein 
that is infrequently seen on immunoblots and does not cross react with 
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monoclonal antibodies raised against glucocerebrosidase lO All three 
molecular forms of glucocerebrosidase are seen in fibroblasts from type 
1 patients, but the 59 kDa and sometimes also the 63 kDa forms are 
deficient in type 2 and type 3 cells. 
Figure 2: Localization of glucocerebrosidase in control (81RD238) (A) and Gaucher's 
disease type 1 (PRW) (B) skin fibroblasts. The enzyme is visualized by incubation with 
rabbit polyclonal antibodies against glucocerebrosidase and subsequent incubation 
with goat anti-(rabbit IgG) (GAR) conjugated to fluorescein. 
The cell lines used in these studies were also assayed for 
glucocerebrosidase activity with the artificial substrate 4-methyl-
umbelliferyl-IS-D-glucopyranoside in the precence of Triton X-IOO and 
taurocholate (Table 1). By immunoprecipitation of glucocerebrosidase 
with monoclonal antibodies it was estimated that the contribution of 
non-specific IS-glucosidase to the total activity in Gaucher's disease cells 
was approximately 15% (data not shown). The ratio of IS-glucosidase acti-
vity to IS-N-acetyl-hexosaminidase activity is listed in Table 1. 
Subcellullar localization of glucocerebrosidase 
Using light microscopy, glucocerebrosidase could be visualized 
immunocytochemically only in type I fibroblasts. However, the signal 
appeared somewhat weaker than in control cells (Fig. 2.) The label is seen 
in distinct particles that were previously identified by double labeling as 
lysosomes.19 The intracellular compartmentation of the enzyme was 
examined at the ultrastructural level in frozen sections of fibroblasts and 
the results of these studies are illustrated in Figs. 3-8. In control 
fibroblasts (Fig. 3 and 4), immunoreactive material is predominantly 
detected along the lysosomal membrane. Frequently, however, labeling 
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is also found on intralysosomal membraneous arrays in secondary 
lysosomes (Fig. 3). The average number of gold particles observed in 
lysosomes of control cells is approximately eight. Labeling of the rough 
endoplasmic reticulum (RER) and Golgi complex is also observed (Fig. 4), 
but is much less in comparison with the lysosomal labeling. 
Figure 3: Subcellular localization of glucocerebrosidase in normal human skin 
fibroblasts (GRA), using GAR conjugated with 10 nm gold partides as 
immunomarker. Bar 0.1 pm. 
In three of the four type 1 cell lines, the number of gold particles in 
lysosomes is about the same as in control cells (Figs. SA, SC and SD). The 
RER (Fig. SB) and Golgi complex are labeled too. In the fourth type 1 cell 
line the number of gold particles found in the lysosomes is clearly 
reduced (Fig. 6). However, the RER and Golgi labeling are comparable to 
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Figure 4: Subcellular localization of glucocerebrosidase in normal human skin 
fibroblasts (8IRD238), using GAR conjugated with 10 nm gold particles as 
imrnunomarker. A; labeling of the lysosomal membrane. B; labeling of the rough 
endoplasmic reticulum. C; labeling of the Golgi complex. Bars 0.1 )1m. 
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Figure 5: Subcellular localization of glucocerebrosidase in fibroblasts from patients with type 1 
Gaucher's disease. Ai cell line 83RD257; labeling of the lysosomal membrane and the rough 
endoplasmic reticulum (R). B; cell line 543 LAD; labeling of the rough endoplasmic reticulum. C; 
cell line 543 LAD; labeling of lysosomes. Gold particles are localized on the lysosomal membrane 
and on intralysosomal membraneous material (arrow heads). 0; cell line PRW; labeling of the 
lysosomal membrane and intralysosomal membraneous material (arrow heads). Bars 0.1 ]..1m. 
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those in control cells. 
The labeling pattern in type 2 and type 3 fibroblasts is significantly 
different from that in control cells and the majority of type 1 cells. Very 
little cross-reactive material is present in lysosomes, but the number of 
gold particles in RER and Golgi complex appears normal (see Fig. 7 for 
type 2 cells and Fig. 8 for type 3 cells). 
A semi-quantitative estimate of the number of gold particles per lysosome 
in the most informative cell lines is given in Table 2. 
Figure 6: Subcellular localization of glucocerebrosidase in type 1 Gaucher's disease; 
cell line 5519. Bar 0.1 11m. 
DISCUSSION 
Using monospecific antibodies for immunocytochemistry on ultrathin 
frozen sections of cultured skin fibroblasts, we were able to determine for 
the first time the actual, in situ, localization of glucocerebrosidase in cells 
from eight different patients with Gaucher's disease. In control fibroblasts, 
most enzyme appeared to be associated with the lysosomal membrane. 
Approximately eight gold particles were detected per lysosome. The four 
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Figure 7: Subcellular localization of glucocerebrosidase in fibroblasts from a patient 
with Gaucher's disease type 2 (GM877). A; labeling of the rough endoplasmic 
reticulum (RER). B; labeling of the Golgi-complex (G) and RER (R). Lysosomes (L) are 
not labeled. Bars 0.1 )1m. 
103 
Figure 8: Subcellular localization of glucocerebrosidase in fibroblasts from a patient 
with type 3 Gaucher's disease (016745). Lysosomes are weakly labeled, while the labe-
ling of the rough endoplasmic reticulum (R) is normal. Bar 0.1 )lm. 
type 1 cell lines showed distinct labeling of the lysosomal membrane, but 
we observed heterogeneity with respect to the amount of immunoreactive 
material detectable. In three of the four type 1 cases the amount was 
ahnost normal, but in the fourth case it was reduced. Interestingly, 
irnmunoblotting did not distinguish the various type 1 patients. The 
different results may relate to the way in which each mutant enzyme is 
specifically exposed to antibodies in both procedures. Hardly any labeling 
of lysosomes was observed in type 2 or type 3 cases of Gaucher's disease, 
whereas RER and Golgi complex in all the different mutant cell lines were 
normally labeled. 
The near absence of immunoreactive material in lysosomes in type 2 and 
type 3 cells is instructive. Since these cells lack the mature 59 kDa 
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Table 2. Semi-quantitative data on the lysosomal labeling in different phenotypes. 
Code Phenotype Average number of SEMb 
gold particles' 
5519 type 1 1.3 0.2 
JF83AD type 3 1.0 0.1 
83RD257 type 1 7.7 0.5 
81RD238 normal 7.1 0.6 
GM877 type 2 0.8 0.5 
'IFrozen fibroblast sections were examined with the electron microscope, and gold 
particles were counted in randomly chosen lysosomes. In each case 125 lysosomes 
were inspected. 
bISEM; standard error of the mean. 
molecular form of glucocerebrosidase on immunoblots, it is reasonable to 
conclude that this form of glucocerebrosidase is the lysosomal form. 
Indeed, Western blots of lysosomes prepared from fibroblasts on percoll 
gradients reveal the 59 kDa to be the predominant CRM in the lysosome 
(Ginns and Barranger, unpublished data). The 66 kDa and 63 kDa 
biosynthetic forms of the enzyme, which are presumably in transit to the 
lysosomes, and which are detectable on immunoblots, probably account 
for the labeling of RER and Golgi complex. 
Since the 59 kDa form of glucocerebrosidase is the most abundant 
molecular species in control cells, it is obvious tha t deficiency of this form 
wiJllead to a substantial reduction in the total amount of cross-reactive 
material. Our results are, in this respect, in line with recent data of 
Beutler et al. l showing a severe reduction of immunologically detectable 
glucocerebrosidase in fibroblasts of patients with type 2 and type 3 
Gaucher's disease. 
The present information on the subcellular localization of gluco-
cerebrosidase in cultured fibroblasts from different clinical variants 
strongly supports a previous hypothesis by Ginns et al.9•10 in which 
deficient processing of glucocerebrosidase was postulated in type 2 and 
type 3 Gaucher's disease. This has recently been confirmed by direct 
measurement of the biosynthesis of enzyme in mutant cell lines by 
pulse-labeling studies." 
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'The difference in lysosomal localization of glucocerebrosidase in 
fibroblasts from three non-neuronopathic (type 1) patients, on the one 
hand, and patients with neuronal involvement (type 2 and type 3), on the 
other, is striking. It provides a logical basis for understanding the very 
different appearance of these several phenotypes of Gaucher's disease in 
relation to the genetic defect. We speculate that neuronal damage is 
prevented or postponed when a sufficient amount of mutant enzyme with 
some residual activity is present in the lysosome. To substantiate this 
hypothesis it is of importance to extend these studies to other cell types, 
and in particular, to those from neuronal tissues. 
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AN IMMUNOELECTRON MICROSCOPIC STUDY OF GLUCO-
CEREBROSIDASE IN TYPE I GAUCHER'S DISEASE SPLEEN 
R. Willemsen, J.M. van Dongen, J.M.F.G. Aerts, A.W. Schram, J.M. Tager, 
R. Goudsmit, A.J.J. Reuser 
ABSTRACT 
An immunogold labelling procedure was applied to ultrathin cryosections 
and used to study the subcellular localization of glucocerebrosidase in 
lipid-laden "Gaucher cells" in spleen from a patient with type 1 Gaucher's 
disease. Glucocerebrosidase protein was associated with the characteristic 
stored lipid material in large, irregularly shaped vacuoles. As shown by 
double labelling the storage vacuoles contained not only gluco-
cerebrosidase protein but also other lysosomal enzymes. Thus, the storage 
vacuoles can be considered to be secondary lysosomes. The findings 
indicate that although glucocerebrosidase was present in secondary 
lysosomes in this patient the activity of the mutant enzyme was 
insufficient to prevent storage of glucocerebroside in the spleen. 
INTRODUCTION 
Gaucher's disease is an inherited sphingolipid storage disorder caused by 
a deficiency of the lysosomal enzyme glucocerebrosidase1.2• The lipid 
accumulates predominantly in macrophages, in all parts of the 
reticulo-endothelial system"'. Storage cells have a characteristic morp-
hology and are called Gaucher cells. Their identification can be used as 
a diagnostic criterion for Gaucher's disease (for review see Ref. 5). 
Among the different clinical phenotypes of Gaucher's disease, type 1 
(chronic, nonneuronopathic) is the most common. It has a particularly 
high incidence among Ashkenazic Jews. Type 2, the acute, neuronopathic 
form, and type 3, the chronic, neuronopathic form of Gaucher's disease 
are more rareS•6• Clinical differences have been attributed to distinct 
abnormalities in the formation, function and subcellular localization of 
glucocerebrosidase in the various forms of this disease7-11 In fibroblasts 
from normal individuals, glucocerebrosidase is synthesized as a 63 kD 
precursor and converted via intermediate forms to a mature enzyme of 
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59kD11,12, This mature form of glucocerebrosidase is often deficient in 
phenotypes 2 and 37,8,10,11, In type 1 Gaucher's disease the maturation 
process is completed, but the enzyme is catalytically deficient",o, and in 
some instances more labilell , 
Recently, we succeeded in visualizing glucocerebrosidase in situ in 
control and Gaucher's disease fibroblasts by performing immunocyto-
chemistry at the electronmicroscopic leve!'o . 
Colloidal gold was used as electron-dense marker, In three out of four 
type 1 cases studied, a lysosomal localization of glucocerebrosidase was 
observed and the amount of cross-reactive material was near normaL But, 
in the fourth case and in fibroblasts from type 2 and type :3 patients, little 
cross-reactive material was detected in lysosomes'o, In a recent study 
encompassing a total of 36 patients it has been shown that different allelic 
mutations occur in the various clinical phenotypes of Gaucher's disease13, 
One of the characteristic features of type 1 Gaucher's disease is the 
splenomegaly caused by massive accumulation of glucocerebroside in 
macrophages in the spleen, We have, therefore used the immunogold 
labelling procedure to establish the intracellular localization of gluco-
cerebrosidase in the lipid-laden Gaucher cells in the spleen of a patient 
with type 1 Gaucher's disease, For the first time it is shown that the 
mutant enzyme is present in the characteristic lipid-containing storage 
vacuoles (secondary lysosomes) in the Gaucher cells, 
MATERIALS AND METHODS 
Case history 
Patient D (Ashkenazic Jewish) was born in 1947, In 1954 the diagnosis of 
M, Gaucher was tentatively made and was confirmed a few years later by 
bone marrow aspiration, In 1974 the patient underwent a thorough 
medical investigation, At that time he had no special complaints, He was 
not anemic, although subecteric. The liver was palpable 3 em below the 
costal margin, the spleen reached just above the pelvic inlet. The 
hemoglobin concentration was 8,1 mmo1/L, leucocytes 2,9 x 10' /L, 
platelets 52 x 10'/1. At a later examination, in 1985, the abdomen was 
markedly distended. The liver was palpable 4 em below the costal 
margin, the spleen was enormous and filled almost the whole abdomen, 
There was a femoral hernia bilaterally. The hemoglobin concentration was 
5,8 mmo1/L, hematocrit 0.3, reticulocytes 70% 0, leucocytes 1.7 x 10' /L, 
platelets 54 x 10'/1. The haptoglobin content was low, 
Splenectomy was planned because of the risk of incarceration of the 
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herniae, mechanical complaints and the hypersplenism. After a very 
careful preparation the splenectomy was performed in November 1986, 
and a spleen weighing 13 Kg was removed. The postoperative course was 
undisturbed. After the operation the patient felt much better. In July 1987 
the Hb concentration was 9.9 mmol/L, hematocrit 0.49, leucocytes 13.4 x 
10' /L and platelets 320 x 10'/1. 
Light and Immunoelectron microscopy 
Immediately after splenectomy, small pieces of the spleen were fixed in 
0.1 M phosphate buffer (PB) pH 7.3, containing 1% acrolein and 0.4% 
glutaraldehyde. After fixation for 24 hrs at 4°C, the specimens were 
stored in 0.1 M PB containing 2% paraformaldehyde and 1 M sucrose. 
Frozen sections were made as described beforelO, using an LKB Nova 
ultratome equipped with the Cryo Nova, at -110°C. Thick sections (0.5 
pm) were stained with 0.4% Toluidine blue. Immunolabelling on ultrathin 
sections (approximately 60 nm) was performed as described beforelO. 
Antigen-antibody complexes were visualized through binding of goat 
anti-(rabbit IgG) antibodies conjugated with 10 nm colloidal gold (GAR 
10, Janssen Pharmaceutica, Belgium). To localize two antigens 
simultaneously, the first antibody was labelled with a 5 nm protein 
A-gold probe and the second with a 10 nm probe, according to Geuze et 
al.14 
Sections were stained with uranylacetate, embedded in 1.5 % methyl-
cellulose, and examined with a Philips EM 400 at 80 kV. As a check on 
the specificity of the labelling procedure, sections were incubated with 
normal rabbit serum as substitution for the primary antibody, GAR-lO 
conjugate alone or with protein A-gold (<\> 5 nm) only. Background 
labelling was negligible. 
Antibodies 
Immunocytochemistry was performed with affinity-purified rabbit 
polyclonal antibodies against homogeneous human placental glucocere-
brosidase'. For double labelling studies, a mixture of affinity-purified 
rabbit polyclonal antibodies against human acid a-glucosidase!5, N-ace-
tyl-B-hexosaminidase!5, B-galactosidase!6 and acid phosphatase!' (tartrate 
inhibitable) were used. 
Biochemical procedures 
Immediately after splenectomy pieces of the spleen were quickly frozen 
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in liquid nitrogen and stored at -70°C until used. Tissue was ho-
mogenized in 50 mM potassium phosphate buffer (pH 6.5) containing 
0.25% (v Iv) Triton X-l00, and glucocerebrosidase activity was determined 
as described by Jonsson et aL" using 4-methylumbelliferyl-fS-glucoside as 
substrate. Glucocerebrosidase was immunoprecipitated from an extract 
prepared from 50 mg of either control spleen or Gaucher spleen. 
Molecular species of the glucocerebrosidase were separated by polyacryla-
mide gel electrophoresis according to Laemmli18, and electrophoretically 
transferred to nitrocellulose". Glucocerebrosidase was visualized with 
enzyme-specific rabbit antibodies7 in combination with goat anti-(rabbit 
IgG) coupled to horse radish peroxidasel1 . 
RESULTS AND DISCUSSION 
Biochemical analysis 
The activity of glucocerebrosidase in spleen tissue of the patient was 0.8 
nmol/h/mg protein as compared with a mean activity of 15.4 ± 1.9 
nmol/h/mg protein in specimens of three different control spleens 
measured at the same time. 
kD 
66· ,,-""<,.~ 
58- ..... ;;:L~ 
control type 1 
Fig. 1 Molecular mass forms of gluco-
cerebrosidase in splenic extracts from a control 
subject and the patient with type 1 Gaucher's 
disease. For experimental details see Materials 
and Methods. Enzyme was isolated from 50 
mg wet weight of spleen. The activity applied 
to the gel was 2.6 nmol/h in the case of the 
Gaucher spleen preparation and 78 nmol/h in 
the case of the control spleen preparation. 
Fig. 1 shows an analysis by immunoblotting of the molecular mass 
species of glucocerebrosidase present in extracts of the patient's spleen 
and of control spleen. In the control spleen, forms of Mr 62-63, 66 and 59 
kD are seen, corresponding to the precursor, intermediate and mature 
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forms of glucocerebrosidase, respectively (see ref. 20). The same forms are 
seen in the spleen from the patient. 
It should be noted that the glucocerebrosidase in each lane was im-
munoprecipitated from extracts prepared from identical amounts of 
tissue. Since the intensity of the bands containing cross-reactive material 
was about the same in the Gaucher spleen as in the control spleen, and 
since the enzymic activity was about 20-fold less in the case of the type 
1 spleen extract, the specific molecular activity (i.e. the activity per 
molecule of glucocerebrosidase protein) must be markedly decreased in 
the patient's spleen. 
Light and Immunoelectromicroscopy 
By light microscopy, numerous large lipid-laden Gaucher cells were 
found in the red pulp of the spleen (Fig. 2). Typically, the nucleus of the 
cells is eccentric and the cytoplasm is structured irregularly, because of 
deposits of glucocerebroside. The fine structure of the storage material in 
Epon embedded tissue sections has been described as arrays of twisted 
tubules 21. The characteristic appearance of the Gaucher cell is well 
Fig. 2 Semithin (0.5 )lm) cryosection of the red pulp of the spleen from the patient 
with type 1 Gaucher's disease. Numerous lipid-laden Gaucher cells are present 
(arrows). 550x. 
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Fig. 3 Subcellular localization of lysosomal enzymes in a Gaucher cell using a mixture 
of antibodies to ()(-glucosidase, N-acetyl-ll-hexosaminidase, ll-galactosidase and acid 
phosphatase in combination with goat anti-(rabbit IgG) antibodies conjugated with 10 
nm gold particles as immunomarker. Lysosomal enzymes are present in irregular, 
enlarged lysosomes (L) with characteristic storage material. 50,000x. N = nucleus 
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preserved in ultrathin frozen sections, as illustrated in Figs. 3-5. There is 
massive storage throughout the cytoplasm. Clearly, the storage compound 
is surrounded by a membrane (Fig. 4, arrows), and the irregular fields of 
storage material are enlarged lysosomes. This was demonstrated by 
incuba ting the cryosections with a mixture of affinity purified antibodies 
against four different lysosomal enzymes and, subsequently, with goat 
anti-(rabbit IgG) antibodies coupled to colloidal gold. Fig. 3 shows heavy 
labelling of the storage vacuoles whereas hardly any gold particles are 
seen in the nucleus or cytoplasmic areas between the storage material. 
Apparently, the lysosomes are still intact although their normal shape is 
completely distorted. 
Fig. 4 Subcellular localization of glucocerebrosidase in a Gaucher cell using an-
ti-(glucocerebrosidase) and goat anti-(rabbit IgG) antibodies conjugated with 10 nm 
gold particles as immunomarker. Glucocerebrosidase is localized in lysosomes in 
association with storage material. The arrows indicate the limiting membrane of the 
lysosome. 45,OOOx. N = nucleus 
The localization of glucocerebrosidase in these Gaucher cells is illustrated 
in Fig. 4 using the same immunocytochemical procedure. Gold particles 
are aligned along the twisted glycolipid tubules. The labelling pattern 
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Fig. 5 Simultaneous subcellular localization of glucocerebrosidase and other lysosomal 
enzymes in a Gaucher cell using protein A coupled to 5 nm and 10 nrn colloidal gold 
particles as irnmunomarkers. Glucocerebrosidase (10 nm gold) and other lysosomal en-
zymes (5 nrn gold) are present within the same lysosome (L). 82,500x. M~mitochondrion. 
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suggests that mutant glucocerebrosidase is associated with its natural 
substrate but is not able to degrade glucocerebroside at a sufficient rate 
to prevent storage of the glycolipid. Thus the picture illustrates exactly 
the situation predicted by biochemical data obtained with spleen a.M.F.G. 
Aerts, unpublished observations) and biochemical" and immuno-
cytochemicallD data obtained with fibroblasts: glucocerebrosidase protein 
is present in near normal amounts and is localized in lysosomes in the 
spleen of this type 1 Gaucher's disease patient, but the mutant enzyme is 
catalytically defective. 
A double labelling procedure with protein A coupled to gold complexes 
of different sizes was used to visualize glucocerebrosidase (10 nrn) and 
other lysosomal enzymes (5 nrn) simultaneously. Particles of both sizes 
are found in the same organelle (Fig. 5). It suggests that glucocerebroside 
does not accumulate in specific storage vacuoles that have lost their 
lysosomal function, but in secondary lysosomes with probably a normal 
content of lysosomal enzymes. 
In conclusion, immunoelectronrnicroscopy on ultrathin frozen sections of 
Gaucher organs can serve as an additional tool to study and characterize 
the different clinical forms of Gaucher's disease. 
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ANIMAL MODEL OF GAUCHER'S DISEASE FROM TARGETED 
DISRUPTION OF THE MOUSE GLUCOCEREBROSIDASE GENE 
VLJ Tybulewicz, ML Tremblay, ME LaMarca, R Willemsen, BK Stub-
blefield, S Winfield, B Zablocka, E Sidransky, BM Martin, S Huang, KA 
Mintzer, H Westphal, RC Mulligan, and EI Ginns 
ABSTRACT 
Gaucher disease is the most prevalent lysosomal storage disorder in 
humans and results from an autosomally inherited deficiency of the 
enzyme glucocerebrosidase (~-D-glucosyl-N-acylsphingosine gluco-
hydrolase)!·', which is responsible for degrading the sphingolipid glucoce-
rebroside. An animal model for Gaucher's disease would be important for 
investigating its phenotypic diversity and pathogenesis and for evaluating 
therapeutic approaches. A naturally occurring canine model has been 
reported but not propagated7• Attempts to mimic the disease in animals 
by inhibiting glucocerebrosidase have been inadequate'. Here we generate 
an animal model for Gaucher's disease by creating a null allele in 
embryonic stem cells through gene targeting and using these genetically 
modified cells to establish a mouse strain carrying the mutation9•lD• Mice 
homozygous for this mutation have < 4% of normal glucocerebrosidase 
activity, die within twenty four hours of birth, and store glucocerebroside 
in lysosomes of cells of the reticuloendothelial system. 
To disrupt the murine glucocerebrosidase gene, a targeting plasmid was 
constructed containing a neomycin-resistance gene inserted into exons 9 
and 10 (Fig. 1a), which encode part of the active site of the enzyme"". A 
herpes simplex virus thymidine kinase gene flanks the construct, allowing 
the use of a positive-negative selection scheme12. This construct was 
introduced into embryonic stem cells by electroporation and the cells 
were subjected to selection with the drugs G418 and gancyclovir12. The 
correct gene targeting event in doubly resistant individual clones was 
identified by Southern blot analysis (Fig. 1b). Of 528 clones screened, 19 
had underdone the homologous recombination event. As gancyclovir 
selection enriched the recombinants by 8.5-fold, the ratio of correctly 
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Figure I. a, Strategy for disruption of the murine glucocerebrosidase gene. The line 
labelled "wild-type" represents the normal genomic structure of the mouse 
glucocerebrosidase gene". Exons 1 to 11 are shown as boxes above the line, with filled 
boxes representing coding regions. The middle line labelled pPNT-MGC2 represents 
the targeting plasmid linearized at a unique Not! site. Neo-mycin-resistance (neo) and 
herpes Simplex virus thymidine kinase (HSV-tk) genes are shown, both transcribed 
from the phosphoglycerate kinase-l gene promoter (shaded boxes with arrows); thick 
line represents the plasmid backbone. The lower line labelled "recombinant" shows 
the structure of the glucocerebrosidase gene after a correct targeting event. Parts of 
exons 9 and 10 and all of intron 9 are replaced with the neD gene. The shaded box 
labelled "A" represents a 32S-bp HincllII/NarI fragment used as probe to identify gene 
targeting events. Predicted sizes (in kilobases, kb) of BamHl digested and Sphl-
digested fragments hybridizing to this probe are shown. band c, Southern blot 
analysis of BamHI-digested genomic DNA from embryonic stern (ES) cell clones and 
from progeny of a germ-line chimaera generated from a correctly targeted clone. In 
b, lane 1 contains normal ES cell DNA from cell line CCE20 and lane 2 contains DNA 
of clone 23-2A-lb, showing a correct targeting into the glucocerebrosidase gene. In c, 
Lanes 3, 4, and 5 contain DNA extracted from tails of mice that are normal, 
heterozygous and homozygous mutant, respectively. DNA in all lanes was digested 
with BamHI and was hybridized with probe A (see a). Sizes of fragments are shown 
in kilobases. Digests of DNA with Sphl gave fragments of the expected sizes on 
Southern blot analysis (data not shown). 
METHODS 
Construct pPNT-MGC2 was made by subcioning a 2,797-bp SspI-Sali fragment 
containing all of exons 5 to 8 and part of exon 9 of the murine glucocerebrosidase 
gene into the XhoI site of pPNT (ref. 21) to create pPNT-MGCl. The glucocerebro-
sidase gene was isolated from a BALB / c DNA phage library and has a map corres-
ponding to that reported in ref. 11. A 3,20S-bp BamHI fragment containing part of 
exon 10 and all of exon 11 was subcloned into the BamHI site of pPNT-MGCl to give 
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pPNT-MGC2. ES cell line CCE20 was grown, electroporated, and selected as 
described21, then injected into C57BL/6 blastocysts". DNA was prepared from ES 
clones and mouse tails and analyzed by Southern blotting as before21 . 
targeted genes was one per 236 stably transformed cells. 
Cells from four embryonic stem cell clones containing the targeted 
mutation in the glucocerebrosidase gene of one allele were injected into 
blastocysts from C57BL/6 mice and transferred to FVB/N foster mice13. 
From these injections, male offspring with more than 30% chimaerism (as 
judged by coat color) were test-bred against C57BL/6 females. One 
chimaeric male, derived from embryonic stem cell line 23-2A16, 
transmitted the glucocerebrosidase mutation to his progeny. Mice 
heterozygous for the disrupted glucocerebrosidase gene were mated and 
homozygous mutant progeny were identified by Southern blot analysis 
(Fig. 1c). As expected, the targeted mutation was transmitted in a 
mendelian fashion. Assay of glucocerebrosidase activity from mouse tails 
demonstrated that in heterozygous mutants the mean activity was 44.4% 
(s.d. ± 2.2%) of that in normallittermates (Fig. 2a). The glucocerebrosidase 
activity in homozygous mutant mice was less than 4% of control, 
confirming tha t the targeted gene disruption had resulted in a null allele. 
Thin-layer chromatography of the neutral glycosphingolipids in tissues 
of normal and homozygous mutant mice demonstrated increased 
glucocerebroside levels only in the mutants (Fig. 2b). 
Homozygous mutant mice are severely compromised at birth, are under 
weight and respire abnormally with rapidly progressing cyanosis, and 
their feeding and movement are decreased (Fig. 3). All homozygous 
mutant mice (n> 100) died within 24 h of birth. Using electron microscopy, 
macrophages with lysosomal lipid accumulation were found in the liver 
(Fig. 4a), bone marrow (Fig. 4b), spleen and brain of homozygous mutant 
mice (n=4), but not in normallittermates (Fig. 4c; n=3) or a heterozygous 
mutant mice. Twenty-five macrophages were examined in each tissue 
specimen. The overall architecture of the liver of the homozygous mutant 
mice appeared appropriate for the early neonatal stage of development, 
demonstrating extensive hepatic hematopoiesis. As in the human disease, 
hepatocytes were not affected and storage was restricted to the Kupffer 
cells in the liver sinusoids'. Stored lipid in the macrophages of the 
homozygous mutant mice has the same physical appearance as the 
tubular lysosomal deposits of glucocerebroside in cells of human patients 
with Gaucher's disease (Fig. 4d)14,15. 
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Figure 2. a, Glucocerebrosidase activity in normal, heterozygous, and homozygous 
mutant mice. Enzyme activity was assayed in mouse tail extracts using 
4-methylumbelliferyl-~-D-glucopyranoside as a substrate as described". b, Thin-layer 
chromatographic of neutral glycosphingolipids in tissues from normal and homo-
zygous mutant mice. Bone marrow (lanes 1), lung (lanes 2), brain (lanes 3), and liver 
(lanes 4) from homozygous mutant (M) or normal (N) mice were extracted and 
analyzed (see Methods). Results shown are from normal and homozygous mutant 
littermates and are representative of data from four homozygous mutant and normal 
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pairs of littermates. The lane marked "5" contains 4 pg of standard glucocerebroside 
(GLI)' The position of glycosphingolipid GLI, running as two bands on the 
chromatogram, is indicated. Glucocerebroside in brain differs from that in extraneural 
tissues, having predominantly CI8 rather than C" fatty acids ceramide moieties". As 
a result of these differences in the fatty acid component, GL l resolves into two 
components. 
METHODS 
Tissues from normal and homozygous mutant mice were extracted with 9.5 ml (v /w) 
of chloroform/methanol (2:1 v/v) with sonication for 10 min at room temperature 
followed by addition of 0.2 volumes water. After vortexing, samples were centrifuged 
for 2 min. A 100-pl aliquot of the lower phase containing the neutral 
glycosphingolipids from each tissue was evaporated to dryness, resuspended in 50 pi 
chloroform/methanol (2:1 v Iv) and applied to precoated silica gel-60 high-
performance thin-layer chromatographic plates (Merck) that had been activated at 
100'C for one h24. The solvent mixture used for development was 
chloroform-methanol-water, 65:25:4 (v /v Iv). After development for 30 min, the plates 
were air-dried, and the glycolipids visualized with orcinol-ferric chloride (Bial's 
reagent)''' . 
Figure 3. Photograph of a homozygous mutant mouse (left) and a normallittermates 
(right) -6 h after birth. In contrast to the normal mouse, the mutant mouse is cyanotic, 
akinetic, has not fed, and has abnormal skin (scale graduated in millimeters). 
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Figure 4. Electron micrographs showing the characteristic morphology of lipid storage 
material in lysosomes of macrophages in the liver (a) and bone marrow (b) of 
homozygous mutant mice with glucocerebrosidase deficiency. In contrast to the more 
rounded lysosome morphology in normal newborn mice (c), the tubular and 
elongated shape of stored lipid gives the lysosomes in homozygous mutant mice a 
more irregular shape. Stored glucocerebroside in the lysosome of a macrophage in the 
spleen of an affected human fetus is shown in d (kindly provided by V.D. Vuzevski). 
L, lysosome; E, phagocytosed erythrocyte; N, nucleus. Scale bars, 0.5 }lm. 
METHODS 
Tissues were fixed in phosphate buffer, pH 7.3, containing 1% acrolein and 0.4% 
glutaraldehyde and postfixed according to ref. 25. Standard procedures were used for 
Epon embedding. 
Although all homozygous mutant mice succumb withill the first day of 
life, no single factor causing death has been identified. Glucocerebroside 
is estimated by thill-layer chromatography to be 5-10pg per mg wet 
weight of liver, lung and brain tissue of mutant homozygous mice at 
birth (Fig. 2b). Less striking amounts of glucocerebroside are seen in bone 
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marrow (Fig. 2b) and plasma. Electron microscopy has demonstrated that 
the storage in lysosomes of macrophages is present but not severe. Thus, 
despite the consistent finding of increased tissue glucocerebroside and 
storage within macrophages in the liver and spleen, there does not appear 
to be sufficient hepatosplenomegaly to explain the rapid deterioration in 
these newborn mutant mice. Soon after birth the homozygous mutant 
mice are always separated from healthy littermates by their mothers and 
neglected, so both the underlying pathology and the maternal perception 
of abnormality probably contribute to the early demise of the newborn 
mutant mice. 
The irregular respiration, poor feeding and decreased movement of the 
mutant mice are consistent with the nervous system dysfunction 
responsible for the fulminant clinical course seen in the more severely 
affected subset of type-2 (acute neuronopathic) infant Gaucher's 
patients',16,'7, Our results may therefore indicate that null mutations 
similar to the one created here could be responsible for the early mortality 
in this subset of infants with lype-2 Gaucher's disease who die of 
neurological disease shortly after birth, so we would predict that indi-
viduals homozygous for these null mutations would not survive beyond 
early infancy, Mutant mice carrying less deleterious mutations could 
therefore be models for the more frequently observed milder 
presentations of Gaucher's disease, 
Mice negative for the enzyme hypoxanthine ribosyl phosphoryl trans-
ferase have been generated by gene targeting, but these were asympto-
matic and were not adequate as a model for Lesch-Nyhan disease,s,19, The 
mice described here may thus be the first example of a mouse model of 
a human genetic disease generated by gene targeting, These mice should 
be useful for studying the pathogenesis and the phenotypic diversity seen 
in Gaucher's disease and will provide a model in which enzyme 
replacement, cellular transplantation and gene transfer therapies can be 
evaluated. 
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A BIOCHEMICAL AND ULTRASTRUCTURAL EVALUATION OF 
THE TYPE 2 GAUCHER MOUSE DEVELOPED FROM TARGETED 
DISRUPTION OF THE MURINE GLUCOCEREBROSIDASE GENE 
R Willemsen, V. Tybulewicz, E. Sidransky, W.K. Eliason, B.M. Martin, 
M.E. LaMarca, A.J.J. Reuser, M. Tremblay, H. Westphal, RC. Mulligan, 
E.I. Ginns. 
ABSTRACT 
Gaucher mice, created by targeted disruption of the glucocerebrosidase 
gene, are totally deficient in glucocerebrosidase and have a rapidly 
deteriorating clinical course analogous to the most severely affected type 
2 human patients. An ultrastructural study of tissues from these mice 
revealed glucocerebroside accumulation in bone marrow, liver, spleen and 
brain. This glycolipid had a characteristic elongated tubular structure and 
was contained in lysosomes as demonstrated by co-localization with both 
ingested carbon particles and cathepsin D. In the central nervous system 
glucocerebroside was diffusely stored in microglia cells and in brainstem 
and spinal cord neurons, but not in neurons of the cerebellum or cerebral 
cortex. This rostral-caudal pattern of neuronal lipid storage in these 
Gaucher mice replicates the pattern seen in type 2 human Gaucher 
patients and clearly demonstrates that glycosphingolipid catabolism 
andlor accumulation varies within different brain regions. Surprisingly, 
the cellular pathology of tissue from these Gaucher mice was relatively 
mild, and suggests that the early and rapid demise of both Gaucher mice 
and severely affected type 2 human neonates may be the result of both 
a neurotoxic metabolite such as glucosylsphingosine and other factors 
such as skin water barrier dysfunction secondary to the absence of 
glucocerebrosidase activity. 
INTRODUCTION 
Gaucher disease in humans and null-allele mice is caused by the inherited 
deficiency of glucocerebrosidase, the lysosomal enzyme that hydrolyses 
the j3-glucosidic bond in glucocerebroside. The major source of this 
glycosphingolipid is the turnover of senescent white and red blood cell 
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membranes. While glucocerebroside is predominantly degraded within 
lysosomes of normal macrophages, accumulation of this lipid in Gaucher 
disease transforms macrophages throughout the mononuclear phagocyte 
system into the characteristic "Gaucher cells". The Gaucher cells have a 
relatively small eccentrically located nucleus, and the cytoplasm contains 
numerous irregularly-shaped or branching lysosomes filled with twisted 
tubular deposits of glucocerebroside (13arranger & Ginns, 1989; Martin, 
Sidransky & Ginns, 1989). 
Gaucher disease has been classified into three subtypes, type 1 (chronic, 
non-neuronopathic), type 2 (acute, neuronopathic) and type 3 (subacute, 
neuronopathic) on the basis of the presence and degree of neurologic 
involvement (13arranger & Ginns, 1989; Martin, Sidransky & Ginns, 1989). 
The clinical manifestations encountered in type 2 Gaucher disease include 
failure to thrive, hepatosplenomegaly, and neurologic deterioration which 
often includes the triad of strabismus, trismus and retroflexion of the 
head. The most severely affected type 2 patients may also have ichthyotic 
skin and/or hydrops fetalis as associated symptoms (Sidransky, Sherer 
& Ginns, 1992). In brains from the few Gaucher patients with neurologic 
involvement that have been studied, perivascular Gaucher cells are found 
and a variable degree of neuronal loss is observed. Neurons with the 
characteristic lysosomal inclusions typically observed in Gaucher cells are 
encountered only sporadically (Banker, Miller & Crocker, 1962; Adachi, 
Wallace, Schneck & Yolk, 1967; Conradi, Sourander, Nilsson, et a!., 1984; 
Kaye, Ullman, Wilson, et a!., 1986; Hernandez & Bueno, 1973). The 
pathophysiologic mechanisms leading to the neurologic symptoms 
observed in these patients remain unknown, largely because of the rarity 
of severely affected type 2 human neonates and the very limited 
opportunities for extensive pathological studies in these patients. 
A Gaucher mouse line recently created by targeted disruption of the 
glucocerebrosidase gene (Tybulewicz, Tremblay, LaMarca, et a!., 1992) has 
provided a relevant animal model for investigation of the 
pathophysiologic mechanisms occurring in type 2 Gaucher disease. In the 
initial report we presented limited pathologic results on these Gaucher 
mice, demonstrating that the deficiency of glucocerebrosidase did result 
in accumulation of glucocerebroside in macrophages. This present report 
describes the more detailed ultrastructural pathology in a variety of 
tissues, including the liver, spleen, bone-marrow and brain from type 2 
Gaucher mice having clinical features characteristic of the more severely 
affected type 2 Gaucher patients. Particular attention is focused on the 
central nervous system, including frontal and occipital cortex, brainstem, 
cerebellum and spinal cord, in an attempt to explain the rapid postnatal 
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demise of these type 2 Gaucher mice and severely affected type 2 human 
neonates. 
MATERIALS AND METHODS 
The Gaucher Mouse 
A Gaucher mouse line was developed by targeted disruption of the 
mouse glucocerebrosidase gene via homologous recombination in ES cells 
(Tybulewicz et a!., 1992). The neomycin resistance cassette replaces part 
of the exons 9 and 10 and abolishes glucocerebrosidase activity in the 
homozygous mutant mice. 
Western Blot Analyses 
Tissue samples were stored at -20°C until use. Prior to extraction, the 
tissue samples were frozen in liquid nitrogen and then crushed into a fine 
powder. The powdered tissue was resuspended in 200-250 )11 of 60mM 
potassium phosphate, pH 5.9, containing 0.1 % Triton X-100, and sonicated 
three times each for 10 seconds (50 Watts, Heat Systems Ultrasonics Inc., 
Cell Disrupter Model W225R) at 'lee. After sonication the samples were 
centrifuged at 12,000xg at 4°C for 5 minutes, and the supernatant used for 
enzyme assay and Western Blot analyses. Protein concentration was 
determined with the Pierce BCA reagent using the recommended protocol 
with BSA as a standard. Enzyme assay was performed using 4-
methylumbelliferyl-~-D-glucopyranoside as substrate (Beutler & Kuhl, 
1970). 
Polyacrylamide gel electrophoresis was performed using precast 12% 
minigels (NOVEX, 1.0mm thickness) at constant current of 40ma using 
reducing, denaturing conditions. Each lane contained 36 )1g of tissue. 
After electrophoretic separation, the proteins were transferred to 
Immobilon-P (Millipore) using 25mM tris, 192 mM glycine, 20 mM 
methanol as buffer. The membrane was briefly rinsed with water and 
incubated in a blocking solution (5% milk powder, 0.05% Tween-20, PBS 
pH 7.2) at 37°C for 1 hr. The membrane was then incubated with rabbit 
antibody specific for mouse glucocerebrosidase (diluted 1:5000 in blocking 
solution) for 1 hr. at 37°C, washed five times for 5 minutes at 37°C with 
PBS pH 7.2 containing 0.05% Tween-20, and finally incubated with goat 
anti-rabbit IgG-HRP (human serum absorbed, Sigma Chemical Co.) at a 
dilution of 1:5000 in blocking solution for 30 minutes at 37°e. The wash 
was then repeated 5 times each for 5 minutes in PBS pH 7.2 containing 
0.05% Tween-20 at 37°e. The antibody-protein conjugate was detected 
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with the ECL Detection Kit (Amersham) using the recommended proto-
coL After the antibody-protein signals were developed, the membrane 
was rinsed with water and protein standards (Nova Wide range SDS-
PAGE protein standards) were visualized with Sulforhodamine B (50 
mg/liter in 30% methanol, 2% acetic acid, Molecular Probes Inc., S1307). 
Glycosphingolipid Analyses 
Liver and brain tissue from normal, heterozygous and mutant 
homozygous mice were extracted with 18 v /w of 2:1 
chloroform-methanol by sonication for 10 minutes at RT, followed by 
addition of 0.2 volumes of water. After vortexing, samples were 
centrifuged for 2 minutes at 12,000xg. A 100 ul aliquot of the lower phase 
was evaporated to dryness, resuspended in 2:1 chloroform-methanol, and 
applied to precoated silica gel-60 high-performance thin-layer 
chromatography plates (Merck) that had been activated at lOO°C for 1 
hour (Kundu, 1981). Development was performed with a solvent mixture 
of chloroform-methanol-water, 65:25:4 (v /v /v) for 45 minutes. The plates 
were then air dried and the glycolipids visualized with orcinol-ferric 
chloride (Bial' s) reagent. 
Tissue processing for Epon embedding 
Liver, spleen, bone-marrow and brain from normal and homozygous 
mutant mice were fixed in 0.1 M phosphate buffer (PB), pH 7.3, 
containing 1 % acrolein and 0.4% glutaraldehyde. After fixation for 24 hrs. 
at 4°C, the tissues were stored in 0.1 . M PB, containing 2% 
paraformaldehyde. Postfixation was performed according to De Bruyn et 
aL, (DeBruyn & DenBreejen, 1976). Specific areas of the brain were 
selected for epon embedding i.e. the frontal and occipital cerebral cortex, 
the cerebellum, the brainstem and the cervical part of the spinal cord. 
After epon embedding a further selection was made for the red nucleus, 
the vestibular nucleus and the facial nerve nucleus of the brainstem. 
Ultrathin sections were cut with a LKB ultra tome NOVA and stained 
with uranylacetate and lead citrate. 
Macrophage marking 
A suspension of carbon particles (India ink) was injected intravenously 
into normal and homozygous glucocerebrosidase deficient mice seconds 
prior to sacrificing the animals. The liver was fixed as described above. 
Immunocytochemistry 
Spleen from normal and affected mice was fixed and stored as described 
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above, but no postfixation was performed. Specimens were embedded in 
Lowicryl K4M according to standard procedures (DeBruyn & DenBreejen, 
1976). Immunolabelling of Cathepsin D on ultrathin sections was 
performed as previously described (Armbruster, Carlemalrn & Chiovetti, 
1982). Sections were stained with uranylacetate and lead citrate. Sections 
incubated with normal rabbit serum showed negligible labelling. 
RESULTS 
Biochemical Findings 
The type 2 Gaucher mouse described in this report was produced by 
targeted disruption of the glucocerebrosidase gene. The affected mice are 
"null mutants" of Gaucher disease, where glucocerebrosidase is 
completely deficient. This is illustrated in Figures la by the absence of 
glucocerebrosidase protein in brain tissue of affected animals. Western 
blot analyses of brain and liver (not shown) from normal and 
heterozygous mice (Figure la) show that the major form of crossreacting 
material (CRM) to mouse glucocerebrosidase has an apparent molecular 
weight of 56 kDa. 
Thin-layer Chromatographic Analyses for Glucocerebroside 
Elevated glucocerebroside levels were demonstrated in brain (Figure Ib) 
and liver (Figure lc) of homozygous mutant mice. The difference in 
mobility of glucocerebroside from brain compared to that from liver or 
the standard is consistent with the heterogeneity in fatty acid moieties of 
the lipid, being C24 in liver or standard and C'8 in brain (Svennerholrn, 
Hakansson, Mausson & Nilsson, 1982). No elevation of glucocerebroside 
is observed in heterozygous mice. 
Macrophages in Bone Marrow, Liver and Spleen 
Except for the dramatic changes observed in the skin (Sidransky, Sherer 
& Ginns, 1992), at the light-microscopic level no definite pathological 
changes were observed. Typical Gaucher cells, easily observed in bone-
marrow, liver and spleen of affected humans were not readily identified 
in the neonatal mouse organs. Therefore, we performed electron-
microscopy to obtain information about the presence and precise 
localization of stored glycolipid. The overall cellularity of the bone 
marrow was identical in normal and mutant mice. Bone marrow from 
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Figure 1. (A) Western blot analysis of glucocerebrosidase in brain of normal (lane 1), 
heterozygote (lane 2), and homozygous mutant mice (lane 3). Sample preparation, 
electrophoresis, and Western blot analyses were performed as described in Materials 
and Methods. Each lane contains 36ug of protein; (B and C) Thin-layer chro-
matography of neutral glycosphingolipids from brain (B) and liver (C) of normal (lane 
1), heterozygote (lane 2), and homozygous mutant (lane 3) mice. The lane marked Std 
contains 4 ug of glucocerebroside (GL I ) standard. 
both normal and mutant mice is shown in Figure 2. Storage of 
glucocerebroside was observed only in macrophages from homozygous 
mutant mice, where the glucocerebroside is deposited in elongated 
tubular arrays which gives the lipid laden lysosomes their characteristic 
irregular shape. 
In these type 2 Gaucher mice the lysosomal accumulation of glycolipid 
was most obvious in the liver. A high power magnification of a Kupffer 
cell is shown in Fig. 3. The lysosomes were marked in this experiment by 
intravenous injection of carbon particles prior to sacrificing the animals. 
In Fig. 4 the lysosomal nature of the storage organelles is demonstrated 
by the co-localization of the lipid deposits and the lysosomal marker 
enzyme cathepsin D. The figure shows a Lowicryl K4M ultrathin section 
of the spleen from a Gaucher mouse on which immunocytochemistry was 
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Figure 2. (a) Ultrathin epon section of bone marrow of homozygous mutant glucocerebrosi-
dase deficient mice; (b) Stored glucocerebroside (SP) is observed within a lysosome (arrow). 
N, nucleus; M, mitochondrion; E, erythrocyte. Bar represents l.Opm in 2a and O.25pm in 2b. 
performed. The gold particles marking cathepsin D were located along 
the twisted glycolipid tubules in the lysosomes in spleen. The 
accumulation of lipid was consistently seen in homozygous mutant mice 
(n=10), but never observed in macrophages from normal (n=5) or 
heterozygous (carrier) mice (n=2). 
141 
Figure 3. Ultrathin epon section of liver of homozygous mutant glucocerebrosidase 
deficient mice sacrificed after intravenous injection of carbon particles. The lysosomes 
(L) of the Kupffer cells are marked by the ingested carbon particles (arrows) that 
colocalize with the stored material. G, Golgi complex; N, nucleus; M, mitochondrion; 
bar represents O.2]lm. 
Macrophages in the central nervous system 
Typical Gaucher cells were not observed in histological serial sections of 
the brain of glucocerebrosidase deficient mice. However, examination of 
the selected areas of the brain (n=6; see materials and methods) revealed 
at the subcellular level microglia with lysosomal accumulation of lipid in 
tubular arrays which was not seen in normal mice (Figs SA and B). 
Macrophages throughout the central nervous system did contain dense 
material, but in this respect the glucocerebrosidase deficient mice were 
not different from the normal. No lipid storage was observed in either 
astroglia cells or oligodendrocytes. The various cell types were distin-
guished by morphological criteria. 
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Figure 4. Ultrathin Lowicryl K4M section of spleen of homozygous mutant mice 
immunogold labeled for lysosomal cathepsin D. The labeled structure is an elongated 
lysosome (L). Cathepsin D is associated with the twisted tubular deposits. N, nucleus; 
bar represents O.2)lm. 
Neurons 
Lipid storage was not detected at the light-microscopic level in neurons 
in brainstem, cerebellum or spinal cord, and hence electronmicroscopic 
studies were performed. In brainstem of mutant mice (n=2), 
glucocerebroside was seen within neurons of the red nucleus (Fig 6a) and 
the vestibular nucleus (Fig. 6b) but not in the neurons of the facial nerve 
nucleus (Fig. 6c). Lysosomal storage was also observed in both sensory 
and motor neurons of the spinal cord (n=2) (Fig. 7), but not in the 
cerebellum or the occipital and frontal cerebral cortex (n=3, data not 
shown). 
DISCUSSION 
The ultrastructural pathology of the type 2 Gaucher mouse was studied 
in an attempt to explain the rapid postnatal death of these mice and 
severely affected type 2 neonates. The cellular and tissue pathology was 
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Figure 5. Ultrathin epon section of cerebellum of normal (a) and homozygous mutant 
mice (b). Microglia in the central nervous system of healthy animals do contain occasi-
onally enlarged lysosomes (L) which are associated with normal function (Sa). 
Lysosomes (L) filled with the characteristic deposits of glucocerebroside are only 
found in microglia of affected animals. The storage material gives the lysosome the 
irregular shape of a network spreading throughout the cytoplasm (5b). N, nucleus; bar 
represents O.5Pffi in Sa and 5b. 
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Figure 6. Ultrathin epon section of brainstem of homozygous mutant mice. Neurons 
of the red nucleus (a) and vestibular nucleus (b) have lysosomes (L) with storage 
material, but lysosomal storage was not observed in neurons of the facial nerve 
nucleus (c). M, mitochondrion; G, Goigi complex; N, nucleus; bar represents O.2]lm 
in 6a, 6b and 6c. 
Figure 7. Ultrathin epon sections of sensory (a) and motor (b) neurons in the spinal 
cord of homozygous mutant mice. The arrows indicate the array of lipid tubules 
present in the lysosomes (L). G, Golgi complex; N, nucleus; bar represents O.2]lm in 
7a and 7b. 
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remarkably mild, despite the complete deficiency of glucocerebrosidase. 
Although the overall architecture of the liver, bone marrow, spleen and 
brain appeared appropriate for age as judged by light microscopy, 
accumulation of glucocerebroside was clearly demonstrated by 
electronmicroscopy. The stored lipid in macrophages of the liver and 
spleen had the characteristic elongated tubular structure (Willemsen, 
VanDongen, Aerts, et aI., 1988; Lee, Worthington & Glew, 1973; Lee, 1982) 
and was contained in organelles identified as lysosomes by the presence 
of ingested carbon particles and lysosomal cathepsin D. Interestingly, 
even though these storage vacuoles did occasionally occupy significant 
cellular volume, typical Gaucher cells were not observed by light 
microscopy. 
The cellular pathology in the central nervous system of the homozygous 
mutant mice similarly is surprisingly limited, particularly in light of the 
rapid clinical deterioration that occurs. Glucocerebroside is stored 
predominantly in microglia cells and only to a very limited extent in 
neurons. While certain sensory and motor neurons of the brain stem and 
spinal cord were affected, Purkinje cells and neurons of the cerebellar and 
cerebral cortex were free of storage product. This rostral-caudal pattern 
of neuronal lipid storage suggests that glycosphingolipid catabolism 
and/ or accumulation varies between neurons in different brain regions. 
A comparison of the neuropathology of the glucocerebrosidase deficient 
mouse with the human type 2 and 3 patients suggests that in the Gaucher 
patients there is also more deposition of glucocerebroside in microglia 
than in neurons (Adachi, Wallace, Schneck & Yolk, 1967; Banker, Miller 
& Crocker, 1962; Conradi, Sourander, Nilsson, Et aI., 1984; Kaye, Ullman, 
Wilson, et aI., 1986). The limited number of neuropathology studies in 
Gaucher patients consistently demonstrates that Gaucher cells are 
predominantly located in the adventitia of vessels in the cerebral and 
cerebellar subcortical white matter, but the reported involvement of 
microglia and neurons in the different regions of the brain is more varied. 
An increasing gradient of Gaucher cells was observed from frontal to 
occipital cerebral cortex by Kaye et al. (1986), whereas Banker et al. (1962) 
report a comparable density of Gaucher cells in the frontal, temporal, 
parietal and OCcipital cortex. A similar comparison could not be made in 
the mouse model because of the lack of histologically detectable Gaucher 
cells. Neuronal storage was only sporadically found in humans 
throughout the central nervous system albeit with an increasing gradient 
from rostral to caudal, as in the Gaucher mice (Banker, Miller & Crocker, 
1962; Adachi, Wallace, Schneck & Yolk, 1967; Conradi, Sourander, 
Nilsson, et al., 1984; Hernandez & Bueno, 1973). 
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The degree of neuronal loss and neuronophagia in humans varied in 
different nuclei (Banker, Miller & Crocker, 1962; Adachi, Wallace, Schneck 
& Yolk, 1967; Conradi, Sourander, Nilsson, et aI., 1984; Kaye, Ullman, 
Wilson, et aI., 1986; Hernandez & Bueno, 1973). No such dramatic 
pathological changes were observed in the mouse. 
This Gaucher mouse line with a complete deficiency of gluco-
cerebrosidase, provides us with a relevant animal model of the most 
severe neonatal form of Gaucher disease, in which we can conveniently 
study the clinical-pathological progression of this disease. From the 
studies reported here, we conclude that the early demise of affected mice 
is probably not caused by liver, spleen or bone marrow dysfunction, nor 
by neuronal degeneration unless the observed amount of lysosomal 
glucocerebroside accumulation results in neuronal dysfunction before 
gross cellular pa thology occurs. Nilsson and Svennerholm have suggested 
that the neurotoxin glucosylsphingosine (glucosylpsychosine) is elevated 
in the nervous system of type 2 patients (Nilsson & Svennerholm, 1982). 
Hannun et. ai, have recently reported that lysosphingolipids, including 
glucosylsphingosine, are potent inhibitors of both protein kinase C 
activity and phorboldiester binding (Hannun & Bell, 1987), suggesting 
that these sphingolipid derivatives can interfere with signal transduction 
and cellular differentiation (Zeller & Marchase, 1992; Ballou, 1992) and 
thus disrupt neuronal function. 
The unusual skin texture, turgor and lipid composition of type 2 Gaucher 
skin (Sidransky, Sherer & Ginns, 1992; Tybulewicz, Tremblay, LaMarca, 
et aI., 1992; Holleran, Takagi, Menon, Legler, Feingold & Elias, 1993) may 
also be an important factor contributing to the rapid deterioration 
observed in severely affected mice and human neonates. Cerarnides are 
critical components in skin permeability barrier homeostasis (Holleran, 
Takagi, Menon, Legler, Feingold & Elias, 1993), and the functional 
disruption of the skin barrier as a consequence of the absence of 
glucocerebrosidase could result in fluid or electrolyte imbalance 
(Holleran, Takagi, Menon, Legler, Feingold & Elias, 1993; Holleran, 
Menon, Elias, Ginns & Sidransky, 1993; Holleran, Ginns, Menon, 
Grundmann, Fartasch, McKinney, Elias & Sidransky, 1994). Lastly, the 
homozygous mutant mice are rapidly identified by their mothers and are 
ejected from the nest. Thus they have been poorly fed, and as a 
consequence dehydration and hypoglycemia may further hasten their 
demise. 
The opportunity to perform further biochemical and pathological studies 
using this mouse model of type 2 Gaucher disease should further our 
understanding of the basis of neurologic involvement observed in these 
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Gaucher mice and type 2 infants. Investigations using these mice may 
also provide more details of the pathophysiologic mechanisms of systemic 
involvement seen in Gaucher disease and permit the more rational 
development of successful therapeutic interventions. 
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A BIOCHEMICAL AND IMMUNOCYTOCHEMICAL STUDY ON 
THE TARGETING OF ALGLl1CERASE IN MURINE LIVER 
R. Willemsen, J.J.M. Tibbe, M.A. Kroos, B.M. Martin, A.J.J. Reuser, E.!. 
Ginns 
ABSTRACT 
A current hypothesis is that functional glucocerebrosidase needs to be 
delivered to the lysosomes of tissue macrophages to guarantee successful 
enzyme therapy for Gaucher disease. In this study, biochemical and 
immunohistochemical techniques were applied to identify in mice the 
localization of intravenously administered alglucerase (human modified 
placental glucocerebrosidase). Only in liver and spleen a significant 
increase of glucocerebrosidase activity was measured with a maximum 
level at 15 minutes after enzyme infusion. The uptake of enzyme by liver 
was sufficiently high to allow more detailed studies on the (sub )cellular 
distribution of human alglucerase. The enzyme in liver is localized both 
in the endosomalllysosomal system of the Kupffer cells and the 
endothelial cells lining the lumen of the sinusoids. Uptake by both these 
cell types is prevented by mannan. The results suggest that the cellular 
mechanisms responsible for improvement of Gaucher patients receiving 
alglucerase treatment is probably more complicated than previously 
recognized. 
INTRODUCTION 
Glucocerebrosidase (EC 3.2.1.45) is a membrane-associated lysosomal 
enzyme involved in glycolipid metabolism, and is deficient in patients 
with Gaucher disease. This autosomal recessive disorder is characterized 
by accumulation of glucocerebroside in lysosomes throughout the mono-
nuclear phagocyte system. The membranes of senescent red and white 
blood cells are the major catabolic source of the stored glucocerebroside. 
Enzyme replacement therapy has been developed for the treatment of the 
non-neurological type 1 form of Gaucher disease (Barranger & 
Ginns,1989; Grabowski, 1993; Brady & Barton, 1994a; Brady & Barton, 
1994b). 
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In the initial human clinical study, injection of unmodified human 
placental glucocerebrosidase resulted in biochemical but not clinical 
improvement (Brady, 1984; Beutler et ai., 1980). Furbish et a1. observed in 
rats that intravenously injected native glucocerebrosidase was targeted to 
both hepatocytes and non-parenchymal cells (Furbish et al., 1978). 
Subsequently, animal studies revealed that modification of the 
carbohydrate chains of placental glucocerebrosidase to expose mannose 
residues enhanced the uptake of glucocerebrosidase by non-parenchymal 
cells (Furbish et ai., 1981). These conclusions about cell type specific 
targeting of enzyme eventually resulted in the development of alglucerase 
(Ceredase, Genzyme Inc.), a modified placental glucocerebrosidase, the 
terminal mannose residues of which facilitate mannose specific receptor 
uptake (reviewed by Pontow et aI., 1992). Enzyme replacement therapy 
with alglucerase in type 1 Gaucher patients has been very successful 
(Barton et al. 1991), but it is currently controversial whether a high-dose 
(60 IU/kg body weight, every 2 weeks) or low-dose (2.3 IU/kg body 
weight, 3 times weekly) regimen is more appropriate (Figueroa et ai., 
1992; Zimran et ai., 1994). Also, despite the clinical efficacy of alglucerase, 
targeting to macrophages has been suggested to be very low (Sato & 
Beutler, 1993). It has been suggested that the striking improvement of 
Gaucher patients may therefore be the result of uptake of alglucerase by 
other cells than macrophages (Sato & Beutler, 1993). In this present work 
we have studied the in vivo distribution of intravenously administered 
alglucerase in the mouse liver. 
MATERIALS AND METHODS 
Enzyme infusion and tissue preparation 
Female BALB/C mice (8 weeks old) were injected with 0.5 ml of 0.1 M 
phosphate buffered saline (PBS), pH7.4, containing alglucerase (Ceredase, 
Genzyme Inc., 60 IU /kg body weight) or unmodified human placental 
glucocerebrosidase (60 IU/kg body weight). In the uptake competition 
studies, 3 mg/ml Mannan (Sigma, St Louis) was added to the enzyme 
preparation before administration. Mice were sacrificed by CO, exposure. 
The liver and spleen were immediately removed, frozen in liquid nitrogen 
and stored at -700 C until used. 
Biochemical procedures 
Liver and spleen were homogenized and sonicated in 1 % (v Iv) Triton X-
154 
100:water. Glucocerebrosidase activity was measured as described by 
Barneveld et al., using 4-methylumbelliferyl-B-glucopyranoside as 
substrate (Barneveld et al., 1983a). Monoclonal antibody 8E4 was used to 
discriminate between the administered human and endogenous mouse 
glucocerebrosidases (Barneveld et aI., 1983b). Alglucerase was 
immunoprecipitated from 1 ml of a tissue homogenate (82 ]lg protein/ml) 
in 0.1 M PBS containing 1 mg/ml BSA with 8E4 and protein G Sepharose, 
and the activity on the beads was measured as described (Barneveld et al., 
1983b). Alglucerase was immunoprecipitated from a tissue homogenate 
containing 820]lg protein/ml and subsequently analyzed by 50S-PAGE 
and blotting using rabbit polyclonal antibody in combination with 1251_ 
labeled protein A for detection (Willemsen et al., 1987). 
Immunocytochemistry 
For light-microscopic localization of alglucerase in liver, thick (7 ]lm) 
cryostat sections were fixed and incubated as previously described with 
rabbit polyclonal antibody against human placental glucocerebrosidase 
(Hoogeveen et al., 1993). The indirect immunoperoxidase procedure was 
performed with swine anti-(rabbit Ig) conjugated with peroxidase (DAKO, 
Denmark) for the second step. Peroxidase was visualized using 3,3'-
diaminobenzidine.HCl (Serva) as a substrate. Endogenous peroxidases 
were inhibited by a 30 min incubation in PBS-hydrogen peroxide(l%)-
sodium-azide(l %) solution. Sections were counterstained with 
haematoxyline (Gill's). Immunoelectronmicroscopy was performed on 
ultrathin frozen sections using the immunogold method (Willemsen et al., 
1988). Briefly, small pieces of liver were fixed in 0.1 M PBS, containing 3% 
paraformaldehyde for one week and stored at 4° C in O.lM PBS, 
containing 1% paraformaldehyde and 1 M sucrose. Ultrathin frozen 
sections were incubated with rabbit polyclonal antibodies against 
glucocerebroaidase. Antigen-antibody complexes were visualized through 
binding of goat anti-(rabbit Ig) coupled to 10 nm colloidal gold particles 
(Aurion, Wageningen, The Netherlands). Sections were stained with 
uranyl salts and examined in a Philips CM100 at 80 kV. Liver sections 
from mice that were injected with PBS were used as controls. 
RESULTS 
Biochemical identification of Alglucerase 
Intravenous injection of alglucerase (60 IU /kg body weight) resulted in 
a two fold increase of the total glucocerebrosidase activity in mouse liver 
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Figure l.-Immunoprecipitable alglucerase activity in mouse liver (a) and spleen (b) 
after intravenous administration (60 IU/kg/body weight) of unmodified human 
placental glucocerebrosidase and alglucerase in absence or presence of mannan. 
Activity is expressed in nmoles MU per mg protein per hour. 
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Figure 2.-Immunoprecipitable molecular forms of alglucerase in mouse liver (a) and 
spleen (b) as revealed by immunoblotting after intravenous injection of alglucerase in 
absence or presence of malU1an. 
Figure 3.-Immunoperoxidase staining of cryostat sections from mouse liver after 
intravenous injection of (a) PBS; (b,c) human unmodified placental glucocerebrosidase; 
(d-f) alglucerase minus mannan; (g-i) alglucerase plus mannan. Tissues were frozen at 
15 min (a,b,d,g), 120 min (c,e,h) and 1440 min (f,i) after administration. Sections were 
counterstained with heamatoxyline. 300X 
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Figure 4.-Subcellular distribution of alglucerase in an endothelial cell (E) and a 
hepatocyte (H) 120 min after alglucerase injection. Alglucerase in endothelial cells is 
present in plasmalemmal vesicles and larger vacuoles (arrows) and at the plas-
mamembrane (PM), often in coated pits (inset, 78,OQOX). The hepatocyte shows a very 
weak labelling of the endosomal system (arrow heads). SD, space of Disse. 46,500X 
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Figure 5.-Subcellular distribution of alglucerase in a Kupffer cell 120 min after 
alglucerase injection. The enzyme is present in large lucent lysosomes (L). Note that 
alglucerase is predominantly located at the limiting membrane of the lysosome or 
associated with intralysosomal membranous material (arrow head). N, nucleus. 29,000X 
tissue at 15 minutes after injection. The alglucerase activity was 
distinguished from the mouse endogenous glucocerebrosidase activity by 
immunoprecipitation with monoclonal antibody SE4 that identifies only 
human enzyme under the described conditions. The highest activity in 
liver and spleen was recorded at 15 minutes after injection (Fig. 1). The 
half-life of the enzyme in liver and in spleen is 7 and 5 hours, 
respectively. As shown in figure 1 the uptake is inhibited when mannan 
is added to the injected sample. The inhibitory effect is especially evident 
at the first time point after injection (±SO% at 15 minutes). Administration 
of unmodified human placental glucocerebrosidase does result in a 
increase of enzyme activity. The results of inununoblotting studies 
performed to characterize the molecular size of administered gluco-
cerebrosidase in liver and spleen are illustrated in figure 2. Alglucerase 
Western analyses show appearance of cross-reactive material (CRM) of 
±60 kD following alglucerase injection, which is decreased in intensity 
when mannan was infused simultaneously. 
160 
Distribution of Alglucerase in liver 
The cellular localization in liver was studied in thick cryostat sections 
using the indirect immunoperoxidase technique. Cross reactivity of the 
antibodies with mouse (endogenous) glucocerebrosidase was negligible 
(Fig. 3a). Only a very weak labelling of Kupffer cells was observed at 15 
and 120 minutes after intravenous administration of unmodified human 
placental enzyme (Fig. 3b and 3c resp.). In contrast, injection of 
alglucerase resulted in a prominent labelling along both the lining of the 
sinusoids and in the Kupffer cells. The labelling pattern remained the 
same for 24 hours after injection, but the intensity decreased with time 
(Figs. 3d-3f). The inhibitory effect of mannan is shown in figures 3g-3i at 
the corresponding time points of figures 3d-3f. 
The subcellular localization of administered glucocerebrosidase was 
studied using the indirect immunogold method on ultrathin frozen 
sections. The localization of alglucerase in endothelial cells and 
hepatocytes is illustrated in figure 4. In endothelial cells, small 
plasmalemmal vesicles and larger vacuoles are labelled (Fig. 4). 
Figure G.-Subcellular localization of alglucerase in a Kupffer cell 120 min after 
alglucerase injection. This high magnification shows alglucerase at the limiting 
membrane of a lysosome (L). SO, space of Disse; H, hepatocyte. 70,000X 
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The labelling at the plasma membrane is often found in coated pits (Fig. 
4, inset). In hepatocytes there is only sporadic labelling of the endosomal 
apparatus at the baso-lateral side (Fig. 4). In Kupffer cells the alglucerase 
is mainly located in large lucent vacuoles and is often associated with the 
limiting membrane or with membranous material inside the vacuoles (Fig. 
5). Smaller vacuoles with a more dense character are also observed with 
gold particles along the limiting membrane (Fig. 6). 
DISCUSSION 
The current success of enzyme replacement therapy in Gaucher disease 
has been attributed to the more efficient delivery of glucocerebrosidase 
to the lysosomes of tissue macrophages (Brady & Barton, 1994a; Brady & 
Barton, 1994b). When the initial clinical trials with purified unmodified 
human placental glucocerebrosidase did not result in clinical improve-
ment it was suggested that modification of the carbohydrate moieties 
might increase the therapeutic effect of the enzyme as a result of more 
efficient targeting to the Gaucher cells. Indeed, quantitative data on rats 
showed uptake of intravenously injected native glucocerebrosidase by 
both non-parenchymal cells and hepatocytes, while more effective 
targeting to non-parenchymal cells was obtained by modifying the 
carbohydrate chains to expose terminal mannose residues (Furbish e/ al., 
1978; Furbish e/ a/., 1981; Morrone e/ a/., 1981). 
Our present results on the (subcellular) localization of intravenously 
administered unmodified glucocerebrosidase and alglucerase in mouse 
liver confirm the previously observed 'biochemical findings. Following 
injection of unmodified human glucocerebrosidase, only minimal activity 
was measured in liver homogenates and very weak staining in sections 
was obtained, while alglucerase infusion resulted in a significant increase 
of human glucocerebrosidase activity in liver as demonstrated by enzyme 
assay, immunoblotting and immunohistochemistry. However, Kupffer 
cells were not the only target cell for alglucerase. At the light-microscopic 
level there was significant uptake of alglucerase by endothelial cells along 
the lining of the sinusoids, that at least in part appeared to be receptor 
mediated because of the presence of label in coated pits, as revealed by 
electronmicroscopy. The labelling of large vacuoles is suggestive of 
subsequent transport of alglucerase to the endosomal/lysosomal system. 
Furthermore, similar to the normal in vivo situation in both Kupffer and 
endothelial cells alglucerase is predominantly associated with the limiting 
membrane of endosomes or lysosomes. 
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The results of our enzyme uptake inhibition experiments using mannan 
suggest a mannose receptor mediated uptake of most of the administered 
alglucerase in Kupffer and endothelial cells. Since hepatic endothelial cells 
have the classical mannose receptor as evidenced by the capacity to bind 
mannose-BSA, it is conceivable that this mannose receptor is responsible 
for uptake of the mannose terminated enzyme in endothelial cells 
(Hubbard et a/., 1979). However, a second mannose receptor distinct from 
the classical one, as described by Sato and Beutler cannot be excluded 
from having a role in uptake of alglucerase (Sato & Beutler, 1993). 
Sinusoidal endothelial cells are the most active of the non-parenchymal 
cells in binding and internalization of mannose-terminated ligands 
(Hubbard et a/., 1979). In addition to this, the fact that approximately two-
third of the non-parenchymal liver cells are endothelial cells suggests that 
most of alglucerase taken up by liver tissue is targeted to endothelial 
cells, rather than Kupffer cells. 
It is as yet unknown to what extent the alglucerase uptake by endothelial 
cells contributes to the therapeutic effect. One can speculate about the 
possibility that alglucerase mediates the uptake and subsequent 
degradation of serum glucocerebroside by binding to both the substrate 
and the mannose receptor on the endothelial cells. A mouse model with 
mild Gaucher disease would be the ideal means to investigate this 
important issue and facilitate optimalization of enzyme replacement 
therapy for Gaucher disease. 
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Stellingen behorende bij het proefschrift 
GAUCHER DISEASE 
An immunoelectron microscopic and 
biochemical study 
I 
Immunoelectronenmicroscopische lokalisatie van normale en 
gemuteerde eiwitten levert een essentiele bijdrage aan het inzicht in de 
pathogenese van erfelijke ziekten. 
Dit proefschrift 
II 
Gebrek aan informatie over de subcellulaire pathologie van genetisch 
gemodificeerde muizen kan leiden tot onjuiste conclusies. 
Dit proefschrift 
III 
De effectiviteit van de behandeling van Gaucher patienten met 
Ceredase™ kan wellicht verhoogd worden door een meer efficiente 
cellulaire "targeting" van het toegediende glucocerebrosidase. 
Dit proefschrift 
IV 
De prevalentie van de type 1 vorm van de ziekte van Gaucher moet 
worden bepaald aan de hand van het phenotype in plaats van het 
genotype. 
Horowitz et al., Hum Mutation (1994):1-11. 
V 
Bij de in vitro bestudering van de klinische heterogeniteit binnen een 
lysosomale stapelingsziekte verdient het de voorkeur een celtype te 
kiezen waarbij in vivo daadwerkelijk stapeling optreedt. 
Willemsen el a/., UZtraslr Palhol (1993):515-527. 
VI 
In de discussie over de behandeling met hoge-dosis versus lage-dosis 
Ceredase™ van type 1 Gaucher patienten zouden voorstanders van het 
hoge-dosis behandelingsschema moeten aantonen dat dit een beter 
resultaat geeft. 
VII 
Wetenschappelijk onderzoek naar de vermeende positieve bijdrage van 
homeopathie aan de reguliere gezondheidszorg zou zich in analogie 
met de reguliere geneesrniddelen ook moeten richten op de eventuele 
toxische effecten van homeopathische geneesmiddelen. 
VIII 
De fysiologische betekenis van het fructaanmetabolisme in planten kan 
aileen worden begrepen door vergelijking van isogene planten die 
aileen verschillen door de aan- of afwezigheid van fructaan-
stofwisseling. 
Hendry et al., New Phytol (1993):3-14. 
Pilon-Smits et al., Plant Physiol (1995):125-130. 
IX 
Het aanbieden van steeds goedkopere ziektekostenverzekeringen door 
verzekeraars waarbij steeds meer risicograepen worden uitgesloten 
bedreigt de solidariteitsgedachte binnen de gezondheidszorg. 
X 
Het typeert de huidige Nederlandse politiek dat in de discussie of twee 
gedetineerden in een cel mogen worden opgesloten een grate 
betrokkenheid van de politici waargenomen kan worden, terwijl deze 
totaal afwezig is als het gaat om de vraag of psychiatrische patienten 
een kamer met vier tot zes lotgenoten moeten delen. 
XI 
IJzel en ZOAB = Zeer Ongeluk(kig) Asfalt Beton. 
XII 
De verzorging en de opvoeding van kinderen is ook een carriere. 
Rotterdam, 27 september 1995 Rob Willemsen 
